VDAC1 is found at the crossroads of metabolic and survival pathways. VDAC1 controls metabolic cross-talk between mitochondria and the rest of the cell by allowing the influx and efflux of metabolites, ions, nucleotides, Ca 2+ and more. The location of VDAC1 at the outer mitochondrial membrane also enables its interaction with proteins that mediate and regulate the integration of mitochondrial functions with cellular activities. As a transporter of metabolites, VDAC1 contributes to the metabolic phenotype of cancer cells. Indeed, this protein is overexpressed in many cancer types, and silencing of VDAC1 expression induces an inhibition of tumor development. At the same time, along with regulating cellular energy production and metabolism, VDAC1 is involved in the process of mitochondria-mediated apoptosis by mediating the release of apoptotic proteins and interacting with anti-apoptotic proteins. The engagement of VDAC1 in the release of apoptotic proteins located in the inter-membranal space involves VDAC1 oligomerization that mediates the release of cytochrome c and AIF to the cytosol, subsequently leading to apoptotic cell death. Apoptosis can also be regulated by VDAC1, serving as an anchor point for mitochondria-interacting proteins, such as hexokinase (HK), Bcl2 and Bcl-xL, some of which are also highly expressed in many cancers. By binding to VDAC1, HK provides both a metabolic benefit and apoptosis-suppressive capacity that offer the cell a proliferative advantage and increase its resistance to chemotherapy. Thus, these and other functions point to VDAC1 as an excellent target for impairing the re-programed metabolism of cancer cells and their ability to evade apoptosis. Here, we review current evidence pointing to the function of VDAC1 in cell life and death, and highlight these functions in relation to both cancer development and therapy. In addressing the recently solved 3D structures of VDAC1, this review will point to structure-function relationships of VDAC as critical for deciphering how this channel can perform such a variety of roles, all of which are important for cell life and death. Finally, this review will also provide insight into VDAC function in Ca 2+ homeostasis, protection against oxidative stress, regulation of apoptosis and involvement in several diseases, as well as its role in the action of different drugs. We will discuss the use of VDAC1-based strategies to attack the altered metabolism and apoptosis of cancer cells. These strategies include specific siRNA able to impair energy and metabolic homeostasis, leading to arrested cancer cell growth and tumor development, as well VDAC1-based peptides that interact with anti-apoptotic proteins to induce apoptosis, thereby overcoming the resistance of cancer cell to chemotherapy. Finally, small molecules targeting VDAC1 can induce apoptosis. VDAC1 can thus be considered as standing at the crossroads between mitochondrial metabolite transport and apoptosis and hence represents an emerging cancer drug target. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
Introduction
The impression of a 'leaky' outer mitochondrial membrane (OMM), attributed to an unknown membrane structural property, led scientists to focus on transmembrane proteins embedded in the inner membrane as being responsible [1] . During the period spanning 1976-1984, using electrophysiology and electron microscopy [1] , it was unambiguously demonstrated that OMM leak was due to unique anion-selective channels, leading to the identification of voltage-dependent anion channels, or in short, VDACs. The last three decades have seen substantial development in our understanding of VDAC1 structure and function [2, 3] . From being channels considered as 'anionic molecules large enough to feel the distribution of electrical potential' [1] , we now know that VDACs transport cations, such as Ca 2+ , as well as many charged and non-charged metabolites, with selectivity for cations and anions being modified by membrane voltage [1] . Moreover, VDAC mediates metabolic cross-talk between the mitochondria and the rest of the cell [2, 4, 5] . Accumulating evidence also points to VDAC as being a key player in the regulation of mitochondria-mediated apoptosis and implicated in cancer and neurodegenerative disorders [2, [4] [5] [6] . Thus, it is now recognized that VDAC not only plays a crucial role in regulating the metabolic and energetic functions of mitochondria but is also a key player in mitochondria-mediated apoptosis. As such, VDAC appears to be a convergence point for a variety of cell survival and cell death signals. Accordingly, several recent reviews have focused on VDAC as being an essential player in apoptosis [2, 7] , on novel VDAC functions [8] , on VDAC structure and function [9, 10] , on the location and function of VDAC in the sarcoplasmic reticulum membrane [11] , and on the modulation of VDAC and its contribution to the roles played by mitochondria in cell life and death [12] [13] [14] , as well as on the role of VDAC in cancer [5, 6] , in hypoxia [15] and in the Warburg effect [16] [17] [18] .
The present review outlines current knowledge related to VDAC1 as a multi-functional mitochondrial protein regulating cell life and death and its importance for cancer cell survival. Specifically, we highlight recent results related to the modulation of VDAC1 activities by associated proteins and suggest a novel mechanism for VDAC1-mediated release of apoptotic proteins and regulation of apoptosis. We also consider the over-expression of VDAC1 in various cancer types and possible VDAC1-based cancer therapeutic applications.
VDAC isoforms, structure and channel activity
VDAC is a 31 kDa pore-forming protein found in the OMM of all eukaryotes [19] , where it functions as gatekeeper for the entry and exit of mitochondrial metabolites, thereby controlling cross-talk between mitochondria and the rest of the cell.
VDAC
In mammals, three versions of VDAC have been identified, VDAC1, VDAC2 and VDAC3 [20] . The three proteins have similar molecular weights (30-35 kDa), share approximately 70% identity and show structural and functional homology, and all serve various auxiliary functions [2, [21] [22] [23] . The three isoforms are nearly ubiquitous in all tissue types, with VDAC2 and VDAC3 expression levels being lower by one and two orders of magnitude than that of VDAC1 [2, 21] . Human (h)VDAC-2 is, however, abundant in the sperm flagellum [24] . Our current information on VDAC primarily stems from extensive studies of VDAC1 [2, 5, 6, [10] [11] [12] [13] . VDAC3 was also found to be associated with the centriole and to modulate its assembly via interaction with Mps1 [25, 26] .
The three isoforms share several structural and functional similarities yet significant differences exist between them in terms of functionality [22, [27] [28] [29] . Recombinant VDAC1 and VDAC2 demonstrated channel activity upon reconstitution into a lipid bilayer (PLB) [30] . Recently, hVDAC3 was also reconstituted into PLB and showed only slightly voltage-dependent conductance [31] .
While the presence of all three isoforms is not essential for cell survival, it was observed that VDAC2 −/− mice (but not those lacking VDAC1) died in the embryonic stage and could not be rescued by over-expression of VDAC1 [2, 4, 5] . hVDAC-2 expression is associated with neurodegerative diseases, including amylotropic lateral sclerosis (ALS) [32] , hypoxia [33] , epilepsy [34] and Alzheimer's disease [4, 35] , and serves a major role in determining apoptosis rates in disease, particularly cancer [2, 36] . The absence of VDAC1 causes multiple defects in respiratory complex activities of the heart and gastrocnemius, a mixed glycolytic/oxidative muscle. VDAC3 −/− mice develop defects in respiratory complex IV activity only in the heart muscle [37] . Other functional differences between the VDAC isoforms with respect to apoptosis are presented below.
VDAC1, thought to be located exclusively in the OMM, has also been localized to cell compartments other than mitochondria based on immunofluorescence, flow cytometry and EM immunogold labeling [38] . These alternate compartments include the plasma membrane of various cells [38] , the sarcoplasmic reticulum of skeletal muscles [39] , the endoplasmic reticulum (ER) of rat cerebellum [40] , and in caveolae and caveolae-like domains. Accordingly, plasma membrane localized VDAC was proposed and termed plasmalemal (pl)-VDAC1. This version of the channel is thought to contain an N-terminal signal peptide responsible for targeting to the cell membrane [41] . While some studies have detected VDAC on the plasma membrane, this form of the protein remains a matter of dispute [42] . Still, several functions for the pl-VDAC1 have been proposed, including serving as part of the outwardly rectifying depolarization-induced chloride channel complex [43] , being involved in brain tissue volume regulation [44] , and contributing to ATP release and cell volume regulation [45] .
VDAC1 structure
In 2008, the three-dimensional structure of VDAC isoform 1 was determined at atomic resolution by three independent approaches [46] [47] [48] . The structure of hVDAC1 (283 amino acids) was solved in parallel by nuclear magnetic resonance spectroscopy (NMR) [47] and by a novel approach combining nuclear magnetic resonance spectroscopy and X-ray crystallography [46] . The three-dimensional structure of VDAC1 from mouse (mVDAC1) was determined by X-ray crystallography [48] . Mouse VDAC1 differs from human VDAC1 by just four amino acid substitutions, namely threonine 55 to asparagine, methionine 129 to valine, alanine 160 to serine and isoleucine 227 to valine. The three structures are almost identical, featuring a 19-stranded β-barrel and an N-terminal α-helical located horizontally midway within the pore (Fig. 1 ). Unlike other known transmembrane β-barrels, VDAC1 includes an odd number of strands, a consequence of which is that barrel closure is achieved by parallel hydrogen bonding between strands 1 and 19, creating a weak point in the barrel structure [10, 46] . Additionally, the N-terminal helix is required to preserve a cylindrical barrel structure in hVDAC1 [49] . Other studies contributed to further understanding of VDAC1 structure and identification of amino acid residues important for the structure and/or function of the protein [50] [51] [52] [53] .
In contrast to VDAC1, structural characterization of VDAC2 and 3 is rather limited. Recently, the structure of zebrafish VDAC2 was resolved at 2.8 Å resolution, revealing a dimer [54] . This assessment was confirmed in solution by double electron-electron resonance spectroscopy and by cross-linking experiments.
A wide range of biochemical and biophysical studies have addressed the structural arrangement of the N-terminal 25 residues of VDAC1, as well as the functional roles assumed by this domain. Previous studies suggest that the N-terminal domain of VDAC1 can be exposed to the cytoplasm [8] , crosses the membrane [55] or lies on the membrane surface [43] . On the other hand, the three solved 3D VDAC1 structures suggest that the N-terminal region of VDAC1 is located inside the pore and that a helical conformation is present within the N-terminal region, which is attached to the channel wall but is not a part of it [46] [47] [48] . The N-terminal region interacts with the β-barrel wall and is stabilized by several hydrogen bonds [48] . The position of the N-terminal region α-helix (comprising residues Tyr-7 to Val-17) within the barrel is approximately at the midpoint of the channel well [46] . Similar positioning was seen in the crystal structure of mouse VDAC1, with the helical region formed by amino acids 6-20 but being broken into two segments at Leu-10-Gly-11. Residues 11-20 were difficult to observe by solution-state NMR, suggesting the dynamic behavior of this segment [47] . A breaking of the helix at glycine 11 could increase mobility in this region. Another important VDAC1 structural element is the stretch of multiple glycine residues ( 21 GlyTyrGlyPheGly 25 ) present in the sequence [1, 5] that connects the N-terminal domain to β-strand 1 of the barrel and that is highly conserved among mammals [56] . It was proposed that this glycine-rich sequence provides the flexibility required for N-terminal region translocation out of the internal pore of the channel [49] . The GlyTyrGlyPheGly motif is conserved in mammalian VDAC1 and Caenorhabditis elegans but not in yeast.
Accumulating evidence suggests that the N-terminal region of VDAC1 constitutes a mobile component of the channel. In recent studies, the location of the N-terminal domain of VDAC1 within the pore and its translocation were demonstrated using site-directed mutagenesis and cysteine substitution, in combination with a thiol-specific crosslinker [49] . It was further demonstrated that the N-terminal region of VDAC1 exists in a dynamic equilibrium, either located within the pore or freely exposed to the cytosolic face of the β-barrel. Further evidence suggesting that the N-terminal region of VDAC1 in fact constitutes a mobile component of the protein comes from the observations showing that (a) this protein segment exhibits motion during voltage gating [57] [58] [59] , (b) anti-VDAC1 antibodies raised against the N-terminal region of the protein interact with membranal VDAC1 [12, 60, 61] , and (c) this section mediates the interaction of VDAC1 with the antiapoptotic and pro-survival factors, hexokinase (HK)-I, HK-II and Bcl2, suggesting its exposure out of the pore [49, 62] .
Several different functional roles for this domain have also been proposed. It was proposed that it forms a segment of the channel wall, acting as the voltage sensor [58] , this supported by the findings that N-terminal-truncated murine VDAC1 showed no voltage dependence yet exhibited high conductance at all membrane potentials tested [58, 59, 62] . In addition, several mutations in the α-helix (at the conserved Asp-16 and Lys-20 positions) affected the voltage-sensing mechanism of yeast VDAC [63] . The N-terminal segment was further proposed to regulate the conductance of ions and metabolites passing through the VDAC1 pore [48] . Finally, the N-terminal domain was proposed to regulate cytochrome c (Cyto c) release and subsequent apoptosis [49, 62] (see Section 4.6).
VDAC1 channel conductance, properties and regulation
The channel activity of VDAC can be reconstituted in a planar lipid bilayer (PLB) ( Fig. 2A ). Upon addition of purified VDAC1 to one of the compartments (termed the cis-side), VDAC1 exhibits a conductance of 3.5-4.0 nS in 1 M KCl or NaCl, at voltages between − 10 mV and +10 mV across the lipid bilayer [19, 64, 65] . At low voltages (~10 mV), VDAC1 exists in a high conductive state, with the channel being stable in a long-lived open state. At high positive or negative potentials (N 40 mV), VDAC1 switches to lower conductance states and presents multiple sub-states with different ionic selectivities and permeabilities [65, 66] (Fig. 2C ). VDAC channels display ion-selectivity that depends on the voltage across the membrane [66] . In the main conductance state, VDAC1 shows a preference for transporting anions over cations [67] . VDAC1 is permeable to small ions (e.g. Cl − , K + , Na + ) yet also to large anions, such as glutamate [65] and ATP [68] , and to large cations, such as acetylcholine, dopamine [65] and Tris [69] . The closed state remains permeable to small ions but not to larger molecules like ATP and ADP [68] .
The involvement of the N-terminal region of VDAC1, a 25 residuelong sequence containing an α-helical moiety in the voltage gating of the channel has been demonstrated in various studies [49, 58, 59, 62, 63, 70] . A wide range of predictions has been made as to the functional disposition of this domain, ranging from it forming a segment of the channel wall, to acting as the voltage sensor, and to regulating the conductance of ions and metabolites passing through the VDAC pore [58, 67] . Indeed, voltage dependence of conductance was not observed with N-terminal-truncated Δ(26)mVDAC1 that exhibited high conductance at all tested voltages [62, 71] . In addition, several mutations in the α-helix (the conserved Asp-16 and Lys-20) residues and in β-strands β1-β5 (Lys46, Lys61, Lys65 and Lys84) affect the voltage-sensing mechanism of Saccharomyces cerevisiae VDAC (scVDAC) [63] .
Thus, it seems that the N-terminal domain of VDAC1 functions in the regulation of the electrophysiological features of the channel and ion fluxes.
VDAC1 as a multi-substrate transporter
The role of VDAC1 in cellular metabolism is crucial, where it serves as the main interface between mitochondrial and cellular metabolisms. The functions of VDAC1 in metabolism and energy homeostasis are reflected by its facilitation of the transport of ions, nucleotides and other metabolites up to 5 kDa across the OMM [2, 9, 55] (Fig. 3A ).
VDAC1 as a cellular metabolite transporter
VDAC1 allows two-way traffic, mediating the entry of metabolites including pyruvate, malate, succinate, and NADH into mitochondria and the exit of newly formed molecules, such as hemes, from mitochondria [2] . In the open state, VDAC1 allows free shuttling of ATP and ADP. Mitochondria-generated ATP is transported to the cytosol for exchange with ADP, which is utilized for ATP generation via oxidative phosphorylation (Fig. 3A) . The importance of VDAC1 in cell energy and metabolism homeostasis is reflected in the findings that down-regulation of VDAC1 expression resulted in reduced metabolite exchange between mitochondria and the cytosol and inhibited cell growth, showing VDAC1 as essential for energy production and cell growth [60] . In the same way, mitochondrial function is connected to VDAC1 closure, which limits the normal flow of metabolites in and out of mitochondria [72, 73] . Proposed three-dimensional structure of VDAC1. A, C. Side-and top-views of the X-ray crystal structure of mouse VDAC1 [48] in a ribbon representation. The β-barrel is formed by 19 β-strands and the N-terminal helix, colored in pink, is folded into the pore interior. β-Strands 1 and 19 are parallel and colored green and yellow, respectively. B, D. Structure of the dimer formed by VDAC1 monomers with proposed β-strands involved in the dimerization marked 1 and 19, and the residues at the interface annotated (PDB ID: 3EMN). E. VDAC1 in a proposed conformation with the N-terminal domain outside the channel pore where it can interact with other proteins.
The importance of VDAC1 in channeling ATP from the mitochondria to kinases has been presented in several studies. Found in the OMM, VDAC1 is able to interact with proteins that mediate and regulate the integration of mitochondrial functions with other cellular activities. VDAC1 interacts with HK and creatine kinase (CrK) to convert newly generated ATP into high-energy storage forms, like glucose-6phosphate (G-6-P) and creatine phosphate in brain and muscle, respectively. It was proposed that at the contact sites between the inner and outer mitochondrial membranes, VDAC1 forms a complex with ADP/ATP carrier, the adenine nucleotide translocase (ANT), and creatine kinase [74] . The interaction of VDAC1 with hexokinase (HK) allows for coupling between oxidative phosphorylation and glycolysis (see Section 8.1). Regulation of VDAC1 permeability to ATP by dimeric αβ-tubulin was proposed, with αβ-tubulin thought to block VDAC1 conductance, leading to the channel becoming impermeable to ATP [75] . The over-expression of VDAC1 in some cancer cells may be related to its multiple activities, especially those required by high energydemanding cancer cells [6] .
VDAC1 in cholesterol and lipid transport
Cholesterogenesis, the biological synthesis of cholesterol, is greatly elevated in various cancer cells, and especially in hepatocellular carcinoma (hepatoma) cells [76] . In general, cancer cells exhibit a 2-10-fold increase in mitochondrial cholesterol, in comparison to liver mitochondria [77] . This high level of cholesterogenesis results in abnormally elevated mitochondrial cholesterol levels, with the increase occurring in the OMM [78, 79] . For instance, the OMM fraction of Ehrlich or AS30-D tumor cell mitochondria was found to contain 3.5-5 times more free cholesterol than did the OMM from rat liver mitochondria, while a less than 2-fold increase in cholesterol was noted in the IMM [77] . High membrane cholesterol has been shown to alter the fluidity of biological membranes [80] and consequently is detrimental to the function of mitochondria in hepatocellular carcinoma cells [81] and other cell types [79] .
Cholesterol is transported across the OMM (Fig. 3A ) [82] . VDAC1 is considered to be a necessary component of a protein complex engaged in mitochondrial membrane cholesterol distribution and transport and to play an important role in altered cholesterol synthesis and transport in Morris hepatoma cells [83] . Cholesterol import into mitochondria is mediated by a hormone-induced 140-200 kDa multi-protein complex called the transduceosome, which is composed of cytosolic and OMM proteins that control the rate of cholesterol entry into the OMM [84, 85] . This complex includes the OMM high-affinity cholesterolbinding protein translocator protein (TSPO), the steroidogenic acute regulatory protein (STAR), and VDAC1 [86] [87] [88] . TSPO interacts with VDAC1, helping to anchor the multi-protein complex to the OMM and assisting with the binding and import of STAR [87] , and thus serves as a regulator of steroidogenesis [89] . The interaction of phosphorylated STAR with VDAC1 facilitates the processing of the 37 kDa phospho- Fig. 2 . Schematic presentation depicting the planar lipid bilayer reconstitution assay system used to study channel conductance properties. A. VDAC channel activity is measured following its reconstitution into a PLB and measuring the current passing through the channel when a salt concentration gradient or voltage is applied across the bilayer. The membrane serves as a capacitor, while the ions carry the current. The cis side is defined as the compartment to which VDAC was added. Currents were recorded under voltage-clamp using a Bilayer Clamp BC-535B amplifier (Warner Instruments, Hamden, CT). Currents were measured with respect to the trans side of the membrane (ground). The currents were low-pass-filtered at 1 kHz, and digitized on-line using a Digidata 1440-interface board and pCLAMP 10.2 software (Axon Instruments, Union City, CA). B. Coomassie blue-stained purified VDAC1 was isolated from rat liver mitochondria as described previously [430] . C. A typical recording of the activity of purified VDAC1 incorporated into a PLB is presented as current traces obtained in symmetric solution (1 M NaCl) in response to voltage steps from 0 mV to either −10 or −60 mV. When the voltage was changed from 0 to −10 mV, the channel conductance remained constant with time. However, when the voltage was changed from 0 to −60 mV, the current first increased, due to a greater driving force but within less than 1 s the channel conductance decreased. The dashed lines indicate the zero current level (0), the sub-state (s) of the channel and the maximal current (m). D. Multi-channel recordings of the average steady-state conductance of VDAC1 are presented as a function of voltage. The conductance at a given voltage was normalized to the conductance at 10 mV. This voltage-dependent behavior is well known for VDAC1.
STAR to the 32 kDa intermediate [88] . Recently, the 14-3-3 family of adaptor proteins was shown to contain binding motifs for important functional sites in STAR, TSPO, and VDAC1 [90] (Fig. 3A) .
The disruption of cholesterol was deemed responsible for the release of VDAC from membranes in extraction experiments [91, 92] . High cholesterol can reduce the activity of membrane-associated proteins and metabolic cross-talk between the mitochondria and the rest of the cell, cellular energy production by transporting ATP/ADP and NADH between the inter-membrane space and the cytosol and by binding HK, Ca 2+ signaling by transporting Ca 2+ , and cholesterol transport. Also presented are the Ca 2+ influx and efflux transport systems in the outer and inner mitochondrial membranes and Ca 2+ -mediated regulation of the TCA cycle. The activation of pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (ICDH) and α-ketoglutarate dehydrogenase (α KGDH) by intra-mitochondrial Ca 2+ , leading to enhanced activity of the TCA cycle, is shown. The electron transport chain (ETC) and the ATP synthase (F o F 1 ) are also presented. VDAC1 in the OMM is presented as a Ca 2+ channel. In the IMM, the uptake of Ca 2+ into the matrix is mediated by a Ca 2+ -selective transporter, the mitochondrial Ca 2+ uniporter (MCU), regulated by a calcium-sensing accessory subunit (MICU1). Ca 2+ efflux is mediated by NCLX, a Na + /Ca 2+ exchanger. High levels of matrix Ca 2+ accumulation trigger the opening of the PTP, a fast Ca 2+ release channel. VDAC1 function in transport of H 2 O 2 is also presented. Molecular fluxes are indicated by arrows. B. VDAC1 function in cell death -Different models for the release of apoptogenic proteins, such as Cyto c (purple) and AIF (yellow), from the mitochondrial inter-membrane space to the cytosol, leading to apoptosis. These models include: (a) VDAC1 closure and OMM rupture serves as the cytochrome c release pathway -Prolonged VDAC closure leads to mitochondrial matrix swelling and OMM rupture, resulting in the appearance of a non-specific release pathway for apoptogenic proteins; (b) a permeability transition pore (PTP) provides the apoptogenic proteins release pathway -A large conductance pore-forming complex, the PTP, composed of VDAC at the OMM, ANT at the IMM and Cyp D in the matrix, allows apoptogenic protein release; (c) Bax activation, followed by its oligomerization, results in OMM permeabilization -Upon apoptosis induction, Bax becomes associated with mitochondria as a large oligomer/complex forming a Cyto c-conducting channel in the OMM; (d) a pore is formed by oligomerized forms of Bax and Bak -Bax/Bak oligomerization, proposedly activated by BH3-only proteins (e.g. Bid), result in OMM permeabilization and Cyto c release; (e) a Baxand VDAC1-based hetro-oligomer mediates cytochrome c release -The interaction of pro-apoptotic proteins (Bax/Bak) with VDAC forms a cytochrome c release pathway; (f) MAC as the release pathway -MAC, proposed to comprise Bax and/or Bak, offers a high-conductance channel and a putative cytochrome c release channel; (g) oligomeric VDAC1 as a channel for the release of apoptotic proteins -A protein-conducting channel is formed within a VDAC1 homo-oligomer, allowing Cyto c release and apoptotic cell death; (h) mitochondrial Ca 2+ overload induces apoptosis -Upon Ca 2+ overload in the matrix, Ca 2+ transport mediated by VDAC1 across the OMM and by the MCU in the IMM lead to dissipation of the membrane potential, mitochondria swelling, PTP opening, Cyto c release and apoptotic cell death. PTP opening is also accompanying by an efflux of the accumulated Ca 2+ into the cytosol. thus inhibit the metabolic functions of VDAC1 [83] . It was suggested that the increased content of cholesterol in the mitochondria of cancer cells could impact the binding of HK to VDAC1 [77, 93] . Conversely, the increased binding of HK to the mitochondria of cancer cells may play a role in mediating increased synthesis and uptake of cholesterol into the mitochondria of cancer cells [93] . Recently, it has been proposed that a glycine motif (GxxxG) in the N-terminal part of VDAC1, localized between positions 20-24, is responsible for cholesterol binding [94] .
The above findings thus point to VDAC1 as affecting cholesterol synthesis and transport, as well as being subject to cholesterol-mediated regulation. This may carry implications for various mitochondrial activities, including oxidative phosphorylation and apoptosis induction, as well as for the propensity of cancer cells to exhibit a glycolytic phenotype.
Finally, it appears that VDAC1 is involved not only in cholesterol transport across the OMM but could also be part of a complex allowing the transport of fatty acids through the OMM in rat liver mitochondria [95] . It is postulated that VDAC acts as an anchor, linking the longchain acyl-CoA synthetase (ACSL) from the outer surface of the OMM and carnitine palmitoyltransferase 1a (CPT1a), which faces the intermembrane space. In the proposed model, upon activation by ACSL, acyl-CoAs are transferred across the OMM by VDAC1 to the intermembrane space where they are converted by CPT1a into acylcarnitine. Furthermore, it was recently proposed that VDAC behaves as a lipid sensor [96] .
VDAC1 as a Ca 2+ transporter
As a ubiquitous cellular signal, Ca 2+ not only stimulates a number of intercellular events but also triggers cell death pathways, including apoptosis, upon changes in its intracellular concentration. Ca 2+ signals regulate Ca 2+ -dependent enzymes, such as phospholipases, proteases, and nucleases, all of which are important during injury or cell death [97] (Fig. 3A ). In addition to their metabolic and apoptotic roles, mitochondria also serve as a major hub of cellular Ca 2+ homeostasis. Indeed, mitochondrial Ca 2+ homeostasis is fundamental for a wide range of cellular activities, such as control of oxidative phosphorylation [98, 99] , modulation of cytosolic calcium signals [100] , cell death [101] , secretion [102, 103] and reactive oxygen species (ROS) production in cancerous cells [104] . Intra-mitochondrial Ca 2+ controls energy metabolism by enhancing the rate of NADH production by modulating critical enzymes, such as those of the tricarboxylic acid (TCA) cycle and fatty acid oxidation [105, 106] , linking glycolysis to the TCA cycle [107] (Fig. 3A) .
Ca 2+ transport across the IMM is mediated via several recently identified proteins. The mitochondrial Ca 2+ uniporter (MCU) has been identified [108, 109] , as has its regulatory protein, the EF handcontaining protein termed MICU1 (mitochondrial calcium uptake 1) that acts as a Ca 2+ sensor controlling mitochondrial Ca 2+ entry mediated by MCU [110] . The mitochondrial inner membrane protein associated with the control of mitochondrial volume homeostasis, Letm1 (leucine zipper-EF hand-containing transmembrane 1) was also proposed to act as a Ca 2+ /H + antiporter [111, 112] , to be essential for normal glucose metabolism and to alter brain function in Wolf-Hirschhorn syndrome [113] . The function of this protein in Ca 2+ homeostasis has been discussed recently [114] . Efflux of Ca 2+ from the mitochondrial matrix is mediated by the Na + /Ca 2+ exchanger superfamily, with NCLX being the major Ca 2+ efflux mediator [115, 116] ( Fig. 3A ). Ca 2+ transport into the mitochondria is also involved in apoptotic cell death, with Ca 2+ overload triggering Cyto c release and subsequent cell death ( Fig. 3B ) (see Section 4.3).
All of the mitochondrial Ca 2+ transporters are located in the IMM. Thus, to reach these transporters, Ca 2+ must first traverse the OMM. The only identified protein mediating Ca 2+ transport in the OMM is VDAC1. Indeed, VDAC1 is highly Ca 2+ -permeable and modulates Ca 2+ access to the mitochondrial inter-membrane space [117] [118] [119] . Indeed, it has been shown that control of OMM Ca 2+ permeability is mediated by VDAC1 [118, 120] . In another study, VDAC showed higher permeability to Ca 2+ in the closed state, rather than in the open state [119] .
Several lines of evidence suggest that VDAC1 possesses divalent cation-binding site(s): (1) La 3+ and Tb 3+ , which are known to bind to Ca 2+ -binding proteins, induce channel closure when added to VDAC reconstituted into a PLB [117] [118] [119] , (2) ruthenium red (RuR) [117, 121] and ruthenium amine binuclear complex (Ru360) [122] , known to specifically interact with several Ca 2+ -binding proteins [117] [118] [119] , as well as a photo-reactive analogue, azido ruthenium (AzRu) [123] , induce VDAC1 channel closure in a time-dependent manner and stabilize the channel in a closed state, thus prevented permeability transition pore (PTP) opening, (3) VDAC activity is modulated by physiological cytosolic Ca 2+ concentrations [120] , and finally (4) RuR and Ru360 are unable to protect against apoptotic cell death in cells expressing E72Q-VDAC1 [121] .
Recent studies have proposed a novel physiological mechanism whereby the magnitude of Ca 2+ transfer into the mitochondrial matrix is regulated by protein/protein interactions between Bcl-xL and VDAC isoforms 1 and 3, with this interaction promoting matrix Ca 2+ accumulation by increasing Ca 2+ transfer across the OMM [124] . VDAC1 functions in cellular Ca 2+ homeostasis are further reflected in recent studies connecting VDAC1 to the Ca 2+ cross-talk that exists between mitochondria and the endoplasmic reticulum (ER) (see Section 6).
VDAC1 as a ROS transporter
Reactive oxygen species (ROS) are well known as contributing to cell proliferation and cell death [125] [126] [127] [128] . Specifically, cellular levels of ROS are linked to anti-tumor immunity, the oxidative tumor microenvironment, and the proliferation and death of cancer cells [129] . Increased oxidant concentrations lead to cellular transformation promoting tumorgenicity through signaling, yet can also cause damage to DNA, proteins, and lipids. Indeed, promoting oxidative stress selectively kills several cancer cell lines [130] [131] [132] .
Cells possess several anti-oxidant defense mechanisms, including up-regulation of various endogenous molecules, such as glutathione, to protect DNA from oxidative damage [133] [134] [135] [136] [137] , or catalytic removal of reactive species by enzymes like superoxide dismutase (SOD), catalase, and peroxidase [138] . Oxidative stress results when production of ROS exceeds the capacity of mitochondrial and cellular antioxidant defenses to remove these toxic species. Hypoxia, a characteristic of most solid tumor microenvironments, causes a progressive elevation in mitochondrial ROS production (chronic ROS). Prolonged hypoxia stimulates multiple cell types and induces the hypoxia-inducible factors (HIFs) that mediate transcription of a large number of hypoxia-sensitive genes that promote glycolysis, angiogenesis, and erythropoiesis and hence, cellular hypoxic adaptation [139] . It is becoming clear that hypoxia enables cells with persistent levels of elevated ROS to survive.
The major site of ROS production in cells is the mitochondria as a result of respiratory chain reactions, in the form of by-products. In human mitochondria, 1-2% of the consumed oxygen is converted to ROS, such as superoxide anions (O 2 −• ), H 2 O 2 , and hydroxyl radicals [140] . The mitochondrial enzymes MnSOD and Cu/ZnSOD act to cope with the ROS produced [135, 141] . However, about 1% of the ROS escapes elimination and when released to the cytosol can attack and modify DNA, lipids and proteins, thus affecting cell survival [142] . ROS can damage the mitochondrial as well as the nuclear genome, leading to direct and indirect changes in the cell microenvironment and the triggering of tumorigenesis [143] [144] [145] [146] . This requires ROS release from the mitochondria to the cytosol. It has been proposed that the release of ROS may be mediated by mPTP with higher ROS levels, longer mPTP openings and inner membrane anion channel (IMAC) [147] .
Yet, the underlying mechanisms of ROS transport via the OMM and the control of this process are not clear. VDAC1 in the OMM may serve as the major gateway for molecules exiting the intermembrane (IMS) space. Indeed, VDAC1 has been proposed to mediate ROS release from the IMS to the cytosol [148] (Fig. 3B ). Several findings support the participation of VDAC1 in ROS transport from the IMS to the cytosol. HK-I and HK-II bound to VDAC1 decreased ROS release from mitochondria when over-expressed in HEK cells [149] , thereby reducing intracellular levels of ROS [150, 151] . Also, expression of HK-I or HK-II was found to protect against oxidant-induced cell death [150, 152] . Thus, detachment of HK from VDAC1 could lead to increased ROS generation and release to the cytoplasm, subsequently activating cell death. Closure of VDAC1 appeared to impede the efflux of superoxide anions from the IMS, resulting in an increased steady-state level of O2 −• , causing internal oxidative stress and sensitizing mitochondria toward Ca 2+ -induced MPT [153] . Finally, the VDAC inhibitors, 4,4′-diisothiocyanatostilbene-2,2′disulfonic acid (DIDS) and dextran sulfate, inhibited O 2 −• release from the mitochondria to the cytosol [148] . As ROS induces VDAC1 oligomerization (see Section 4.4), leading to the formation of a large pore that allows for passage of Cyto c, the same channel could also serve as ROS efflux channel. Indeed, both VDAC1 oligomerization and ROS release are inhibited by DIDS [148, 154, 155] . ROS promotes Cyto c release from mitochondria [156, 157] . In fact, it has been shown that apoptosis-inducing agents, such as inorganic arsenic compounds [158, 159] and doxorubicin [160, 161] , induce apoptosis by inducing ROS generation. The inhibition of O 2 −• -induced apoptosis by DIDS, an inhibitor of VDAC channel activity, or anti-VDAC1 antibodies [39, 162, 163] , suggests that O 2 −• induces Cyto c release via VDAC1dependent permeabilization of the OMM [162] . Moreover, O 2 −• was found to evoke Cyto c release in VDAC1-reconstituted liposomes [162] .
In other studies, it was found that ROS-induced alterations of VDAC1 and/or ANT could induce MMP selective for Cyto c release, without causing further mitochondrial damage [162, 164] . Moreover, it was shown that ROS-induced up-regulation of VDAC1 can be prevented by the ROS chelator, epigallocatechin [165] . It has been suggested that ROSmediated Cyto c and SOD1 released from mitochondria involve VDAC, leading to increased susceptibility of mitochondria to oxidative stress and apoptosis [166] . As discussed above, the multiple functions of VDAC1 in transporting metabolites, nucleotides, cholesterol and ROS make VDAC1 not only the gatekeeper of mitochondria, regulating cell life and death, but also a critical factor for cancer cell survival.
Mitochondria and apoptosis

Apoptosis pathways
Apoptosis can be initiated by two signaling cascades, termed the extrinsic and intrinsic pathways. The classical extrinsic pathway is triggered by the binding of extracellular signals, like tumor necrosis factor (TNF), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and apoptosis antigen-1 (Fas) ligand (FASL), to death receptors, such as tumor necrosis factor receptor 1 (TNFR1) and FAS [167] . Such interaction leads to the recruiting of an adaptor protein and the initiating protein procaspase 8 to the cytoplasmic domain of the death receptor. This complex, the death-inducing signaling complex (DISC), activates procaspase 8 by auto-proteolysis, transforming it into mature caspase 8 [168] . Caspase 8 then activates caspases 3, 7 and 6, promoting apoptosis, with accompanying increases in proteolysis and DNA degradation.
The intrinsic pathway can be triggered by intracellular stress signals, such as oxidative stress and DNA damage, as well as by various compounds acting as chemotherapeutic drugs. The intrinsic pathway is activated when the diverse signals are sensed by mitochondria through pro-apoptotic signals that overcome anti-apoptotic signals, leading to mitochondria permeabilization and release of intermembrane apoptogenic proteins [169] . The released pro-apoptotic proteins include Cyto c [170] , Smac/DIABLO, AIF and HTRA2/OMI [171, 172] . The Cyto c released to the cytosol interacts with the apoptotic protease-activating factor 1 (Apaf-1), resulting in increased affinity of the complex for dATP whose binding is necessary for oligomerization and formation of the apoptosome [173] . This complex now interacts with the cysteine-aspartic protease pro-caspase 9 to form the apoptosome, which activates the executioner caspases, such as caspases 3 and 7, and subsequent cell distruction [174] . This pathway is regulated at several steps, including the release of Cyto c from the mitochondria by members of the Bcl-2 family of proteins [175] , and that of caspases by the IAP family of proteins [176] . In addition, it is proposed that release of Cyto c from mitochondria is regulated via phosphorylation of Tyr48 in vivo [177] , with mutant Tyr48Glu Cyto c being incapable of inducing downstream caspase activation [178] .
The AIF released from the mitochondria also acts as an effector of apoptotic cell death and upon cleavage by calpains and/or cathepsins, AIF is translocated to the nucleus, leading to chromatin condensation [179] and DNA fragmentation [180] . Thus, released Cyto c and AIF are key steps in apoptosis induction.
The extrinsic pathway can be connected with the intrinsic pathway through the caspase 8-mediated cleavage of Bid into tBid (truncated Bid). The C-terminal tBid fragment translocates into the mitochondria, where it causes (either directly or indirectly) Cyto c release, resulting in apoptosome formation, caspase activation and cell death [168] . Therefore, tBid links apoptotic signals initiated by death receptors to mitochondria-mediated apoptosis. As such, mitochondria serve as both initiators and accelerators of apoptotic signals. The proposed mechanism for Cyto c release is presented below (see Section 4.3).
VDAC involvement in apoptosis
There are several significant findings connecting VDAC1 to apoptosis and proposing that VDAC1 is an important player in the release of apoptosis-inducing proteins from mitochondria to the cytosol [2,3,6-8, 12-14,181] . These include the following observations: (a) Cyto c release, cell death and Bax-VDAC1 interaction were all inhibited by anti-VDAC1 antibodies [162, 182, 183] ; (b) inhibition of Cyto c release and cell death by HK were both shown to specifically rely on interaction with native but not mutated VDAC1 [121, 181, 184] ; (c) RuR interacts with native but not mutated VDAC1 to prevent Cyto c release and cell death [121, 185, 186] ; (d) siRNA-mediated down-regulation of VDAC1 prevented cell death induced by cisplatin and strongly reduced cisplatin-induced release of Cyto c, AIF and maturation of caspase 3 and cell death [187] . VDAC1-siRNA also attenuated endostatininduced apoptosis [188] ; (e) over-expression of VDAC1 was found to induce apoptotic cell death, regardless of cell type [121, 184, [189] [190] [191] . It has been shown that VDAC1 over-expression in endothelial cells enhanced the activation of caspase 9 and elevated the production of ROS and endostatin-induced apoptosis [188] ; (f) VDAC1 was shown to be involved in Cyto c release from proteoliposomes in vitro [162, 192, 193] ; (g) VDAC1-deficient mitochondria from mutant yeast did not exhibit Bax/Bak-induced Cyto c release or Δψ loss [192, 194] ; (h) the BH4 domain of Bcl-xL was found sufficient for inhibition of Cyto c release and Δψ loss in VDAC1 proteoliposomes, as well as in HeLa cells and isolated rat liver mitochondria [192, 194, 195] ; and (i) VDAC1 interacted directly with Bcl2 and Bcl-xL and protected against apoptosis in cells expressing native but not mutated VDAC1 [196, 197] .
Proposed pathways and mechanisms for apoptogenic factors release from the mitochondria
Mitochondria contain an arsenal of apoptogenic factors normally residing in the IMS, such as Cyto c, AIF, Smac/DIABLO and endonuclease G. One of the enigmas in mitochondria-mediated apoptosis concerns the release pathway(s) of these apoptogenic factors from the IMS to the cytosol. Specifically, it remains unclear how these apoptotic initiators cross the OMM for release into the cytosol.
All of the mitochondrial components known to translocate to the cytoplasm following an apoptotic stimulus reside in the IMS. Therefore, only the permeability of the OMM needs to be modified for this event.
To date, several models have been proposed to explain the release of apoptotic proteins from the IMS (for reviews, see [2, 5, 155] ). Some models suggest that release exclusively involves an increase in OMM permeability due to the formation of a channel large enough to allow for the release of proteins, such as Cyto c (Fig. 3B ), while others consider release to be due to disruption of OMM integrity (Fig. 3B ). Briefly, the major models include:
(i) Osmotic matrix swelling -This is a process caused by a defect in mitochondrial ATP/ADP exchange due to VDAC1 closure, leading to OMM rupture and non-specific release of inter-membrane proteins into the cytosol [13, 72, 198] (Fig. 3Ba ). (ii) Permeability transition pore (PTP) -The PTP is a highconductance non-specific pore linking the inner and outer mitochondrial membranes (Fig. 3Bb ). Opening of the PTP, in response to over-production of ROS or Ca 2+ overload, results in free penetration of low-molecular weight substrates into the mitochondrial matrix, along with water, leading to mitochondria swelling and the release of Cyto c into the cytosol [12, [199] [200] [201] .
The proposed major PTP complex components include VDAC1 at the OMM, adenine nucleotide translocase (ANT) in the IMM, and cyclophilin D (CypD), a resident of the matrix [12, 199, 202, 203] . While gene knockout experiments performed in mice have confirmed the contribution of CypD to the PTP, data obtained with mitochondria from cells lacking some but not all ANT isoforms [204, 205] or VDAC [206] have questioned the importance of ANT and VDAC1 for PTP formation. Recently, it was proposed that dimers of ATP synthase form the permeability transition pore [207] . Irrespective of the exact nature of the protein(s) responsible for PTP formation, this entity has been demonstrated to participate in many cell death scenarios. PTP was proposed to serve as a Ca 2+ release channel, with its transient opening offering a fast Ca 2+ release mechanism and with its persistent opening resulting in non-regulated release of matrix Ca 2+ [208] . It was also suggested that the PTP may play a role in necrosis, yet not in apoptosis [203, 208, 209] . (iii) Bax/Bak complexes -Bax and Bak are pro-apoptotic proteins, activity of which is inhibited by the anti-apoptotic members of the Bcl2 protein family. Bax and Bak can, however, oligomerize to form selective large channels sufficient for Cyto c release across the OMM [210] [211] [212] [213] (Fig. 3Bc ). Cytosolic Bax is weakly associated with mitochondria as a monomer, whereas following apoptosis induction, it becomes associated with mitochondria as large oligomers and complexes of 96 kDa and 260 kDa, respectively. Bcl-2 prevented Bax oligomerization and insertion into the mitochondrial membrane [214, 215] . Bak can form homooligomers [216] or hetro-oligomers with Bax to form a pore after their activation by tBid [217, 218] . (iv) Bax/VDAC1 complexes -The existence of hetero-oligomers composed of VDAC1 and Bax forming the Cyto c release channel was also proposed [219, 220] (Fig. 3Bd ). (v) Mitochondrial apoptosis-inducing channel (MAC) -MAC is a supra-molecular high-conductance OMM channel that was also proposed as providing the pathway for Cyto c release [209] ( Fig. 3Be ). The electrophysiological characteristics of MAC are very similar to those of Bax channels. Depletion of Bax significantly diminished MAC activity, suggesting that Bax is an essential constituent of MAC in some systems. Recently, it was proposed that Bax and/or Bak form the MAC [221] . What is clear is that MAC activation is tightly regulated by Bcl-2 family proteins [222] . (vi) VDAC1 oligomerization -A recently proposed model suggests that VDAC1 undergoes conformational changes and oligomerization in response to apoptotic stimuli, with VDAC1 oligomers forming a pore large enough to enable the release of Cyto c, leading to the induction of apoptosis [5, 62, 154, 155, 181, 193, [223] [224] [225] (Fig. 3Bf ).
In support of this model, apoptosis induction was recently shown to be correlated with an increase in VDAC1 oligomerization (up to 20-fold), while the apoptosis inhibitor, DIDS, prevented staurosporine (STS)-induced VDAC1 oligomerization and apoptosis [154, 155] (see Section 4.4). (vii) Ca 2+ overload -Non-physiological Ca 2+ overload depolarizes mitochondria by opening the PTP, with concomitant release of Cyto c and other IMS proteins [226, 227] , leading to apoptotic and possibly also necrotic cell death [208] (Fig. 3Bg ). The mechanism of Ca 2+ -mediated activation of Cyto c release is unclear.
Finally, it should be noted that multiple pathways and mechanisms of Cyto c release could co-exist within a single model of cell death, depending on the cell type and nature of the stimulus [228, 229] .
A VDAC1 oligomeric structure as a Cyto c release pathway
The diameter of the VDAC1 pore in its high conductance state is about 2.6-3.0 nm, sufficient to allow passage of nucleotides and small molecules but insufficient for a folded protein like Cyto c to traverse. As such, the formation of a large channel comprising VDAC1 monomers and serving as the Cyto c release channel has been proposed [5, 154, 155, 193, [223] [224] [225] . Substantial evidence supports the claim that VDAC1 can exist as higher-order oligomers, namely as monomers, dimers, trimers, tetramers, and hexamers, with the formation of higher ordered VDAC1containing complexes having been demonstrated [154, 155, 193, 195, [230] [231] [232] [233] . In several studies, it has been reported that both purified soluble and membrane-embedded VDAC1 can assemble into dimers, trimers and tetramers in a dynamic process [234] . The supramolecular organization of VDAC1 in native OMM has also been demonstrated using atomic force microscopy (AFM) [231, 232] . Chemical crosslinking experiments using both purified and membrane-embedded VDAC1 also revealed the assembly of dimers, trimers, tetramers and higher VDAC1 oligomers [193] . In addition, the application of symmetry operators on the NMR-based structure of recombinant hVDAC1 [46] indicated that it may form a parallel dimer, although analysis of the crystal packing of mouse VDAC1 revealed an anti-parallel dimer, which further assembles into hexamers [235] . On the basis of electron microscopybased analysis of 2D crystallized OMM, it was noted that VDAC1 pores are organized into ordered arrays, each bearing six monomers with inter-channel contacts [236] . Recently it was suggested that the particular lipid composition of the OMM, a profile that changes upon encountering apoptogenic stimuli, significantly enhances VDAC1 oligomerization [237] . VDAC1 oligomerization is a dynamic process, such that equilibrium between monomeric and oligomeric forms exists, as shown by FRET technology [193] .
It has been proposed that dynamic VDAC1 oligomerization mediates the formation of a large flexible pore between individual subunits of VDAC1, serving as a channel that allows Cyto c to cross the OMM [5, 154, 155, 181, 193, [223] [224] [225] . This concept gained experimental support when it was shown that apoptosis induction in cultured cells leads to VDAC1 oligomerization [154] . Release of Cyto c via purified VDAC1 reconstituted into liposomes in which Cyto c was encapsulated has been demonstrated [162, 193] . In response to various apoptosis inducers, VDAC1 oligomerization can be enhanced up to 20-fold, reflecting a shift in VDAC1 status from the monomeric toward the oligomeric form ( Fig. 4 ). Apoptosis-mediated enhancement of VDAC1 oligomerization was obtained regardless of the cell type or apoptosis inducer used, including STS, curcumin, As 2 O 3 , etoposide, cisplatin, selenite, TNF-α, H 2 O 2 or UV light, all affecting mitochondria yet acting via different mechanisms. Additionally, VDAC1 oligomerization and apoptosis show similar concentration-and time-dependence on the apoptosis stimulus involved.
Additional support for coupling between apoptosis induction and VDAC1 oligomerization is presented by the inhibition of both processes by DIDS. DIDS, a known apoptosis inhibitor [154, 155, 238] , also inhibited VDAC1 oligomerization [154] . The relationship between VDAC1 oligomerization and apoptosis is further reflected in studies attributing the apoptosis-inducing effect of As 2 O 3 to induction of VDAC1 homodimerization [183] . This effect was prevented by over-expression of the anti-apoptotic protein, Bcl-xL [183] . Finally, the hepatitis E virus ORF3 protein was found to up-regulate VDAC1 expression, with ORF3expressing cells showing higher levels of oligomeric VDAC1, as revealed by chemical cross-linking [239] .
The results presented above led us to propose a novel model in which VDAC1 exists in a dynamic equilibrium between the monomeric and oligomeric states, with apoptosis inducers shifting the equilibrium toward oligomers (Fig. 4D) . VDAC1 oligomers form a conducting channel that enables the release of Cyto c from the mitochondria, leading to cell death.
Contact sites between VDAC1 molecules in VDAC1 oligomers
The formation of VDAC1 trimers, tetramers, hexamers, and higher oligomers [193, 195, 231, 232] requires more than a single contact site between VDAC1 monomers. The formation of a channel large enough to allow passage of Cyto c (3.4 nm external diameter) [240] requires six cylindrical VDAC1 monomers, each with an external diameter of 4.0 nm (representing the distance between the beta-carbon (Cb) of Phe236 and the Cb of Leu100) [46] [47] [48] , arranged around a central pore 4.0 nm in diameter. The resolved 3D structure of recombinant VDAC1 creates new opportunities for structural studies of VDAC1. Some of the proposed structures suggest that the protein-protein surface in a VDAC1 dimer involves amino acid residues in β-strands 1, 2, 18, and 19 from both VDAC1 monomers [46, 235] , as depicted in Fig. 1 . , then incubated at 30°C with EGS (300 μM, 15 min), followed by SDS-PAGE (10 % acrylamide) and Western blotting using anti-VDAC1 antibodies. VDAC1 monomers, dimers and multimers are indicated. The asterisk represents intra-molecular cross-linked monomeric VDAC1. B. Similar to A, Hela cells were incubated with the indicated concentrations of selenite for 16 h and treated as previously described. C. The extent of apoptosis as a function of VDAC1 dimer level. Apoptsis and VDAC1 oligomerization were induced in HeLa cells by selenite (0-10 μM, 16 h). Apoptotic cell death assayed using annexin V-FITC, PI staining and FACS analysis. D. Model for VDAC1 oligomerization and its N-terminal region-mediated cytochrome c release. (a) Before apoptosis induction: Side-view across the membrane with VDAC1 in the monomeric state and with the amphipathic α-helix N-terminal region cytoplasmically exposed [8] or positioned within the pore [46] [47] [48] . (b) Upon an apoptotic signal: VDAC1 oligomerization is enhanced and the amphipathic α-helix N-terminal region of each VDAC1 molecule flips into the hydrophobic pore formed by the β-barrels, forming a hydrophilic pore capable of conducting Cyto c release. (c) Inhibition of apoptosis by anti-apoptotic proteins: HK [62] , Bcl-xL [196] or Bcl-2 [197] interact with the N-terminal region of VDAC1 to prevent its translocation and thus, the formation of the hydrophilic pore, thereby inhibiting Cyto c release.
Thus, it is likely that other interface sites (besides those between βstrands 1 and 19) exist within VDAC1 oligomers. In fact, when VDAC1 monomers containing a single cysteine (C232 in β-strand 16) were exposed to thiol specific cross-linker BMOE, dimers were obtained, suggesting that C232 from each of the two VDAC1 monomers face each other and are in close proximity (b8 A) within a dimer arrangement [241] . This finding is surprising since according to recent VDAC1 topology models [46] [47] [48] , C232 faces the channel pore. Our results suggest that this residue can also be exposed outside the pore toward the bilayer and undergo cross-linking. Furthermore, VDAC1 dimers were also formed when a cysteine substitution was introduced at A231 in β-strand 16 of ΔCys-rVDAC1, providing support for the proposal that β-strand 16 is involved in another contact site in VDAC1 dimers [241] .
The VDAC1 N-terminal domain and the release of Cyto c
The proposed VDAC1 oligomeric channel comprises a β-barrel that is expected to be hydrophobic. It can thus be asked how positively charged Cyto c could traverse such a pore. The finding that no apoptosis was induced in cells expressing an N-terminal truncated form of VDAC1 shows that the N-terminal domain of VDAC is required for the release of Cyto c and apoptotic cell death [62] . The proposed function of the N-terminal region in apoptosis is thus based on the requirement of this domain for apoptosis yet not being essential for VDAC1 oligomerization [62] . Structural studies place the VDAC N-terminal region within the channel pore, yet biochemical and functional studies reveal that the N-terminal domain is cytoplasmically exposed (see Section 2.2). Thus, it has been proposed that upon apoptosis induction and concomitant with VDAC1 oligomerization, the amphipathic N-terminal domain is translocated from the pore interior into a newly formed oligomeric structure [49, 224, 238] (Fig. 4D) . This relocated N-terminal domain converts the hydrophobic pore into a pore that instead presents a hydrophilic environment, conducive to the passage of Cyto c and other apoptotgenic proteins across the OMM [49, 62, 154, 224, 238] (Fig. 4D) . This suggestion is supported by circular dichroism (CD) and NMR studies showing that a synthetic peptide corresponding to VDAC1 residues 2-20 exists as an unstructured peptide in aqueous solvent yet forms a well-ordered α-helix from residues 5-16 in SDS [242] . Moreover, the glycine-rich sequence in the N-terminal domain was shown to provide the flexibility required for its translocation out of the internal pore of the channel [49] . The location and translocation of the VDAC1 N-terminal domain as a target for anti-apoptotic proteins were demonstrated by site-directed mutagenesis and cysteine substitution, together with a thiol-specific cross-linker [49] . These studies showed that the VDAC1 N-terminal region exists in a dynamic equilibrium, located within the pore or exposed outside the β-barrel, and that this translocation to the cytsol is required for binding of HK and anti-apoptotic proteins, Bcl2 and Bcl-xL [49, 62, 196, 197] .
VDAC1 over-expression and cell death
Exogenous VDAC over-expression induces cell death
Numerous studies using silencing or over-expression approaches suggest that the expression level of VDAC1 plays a critical role in mitochondria-mediated apoptosis [2, 62, 121, 184, [189] [190] [191] 223, 233] . Over-expressing human, murine, yeast, Paralichthys olivaceus, or rice VDAC was found to induce apoptotic cell death regardless of cell type [121, 184, [189] [190] [191] by an as yet unknown signaling pathway. Such VDAC1 over-expression resulted in apoptosis, as reflected by cell staining with annexin V, membrane blebbing, chromatin condensation and fragmentation, and Cyto c release [223] . It was demonstrated that VDAC1 over-expression is associated with VDAC1 oligomerization, shifting the equilibrium toward the oligomeric state and allowing the release of pro-apoptotic proteins, leading to cell death [62, 223, 233] (see Section 4.4). VDAC1 over-expression-induced cell death was prevented by RuR [121, 185] , Bcl2, DIDS [191] or by over-expression of HK-I [121, 184, 243] , with all these agents directly interacting with VDAC1. These results show that the cellular expression level and oligomerization state of VDAC1 are crucial factors in the process of mitochondria-mediated apoptosis.
Apoptosis stimuli induce VDAC1 over-expressiona new mode of action
Several studies demonstrated an increase in VDAC1 expression levels following apoptosis induction by pro-apoptotic drugs or conditions (Table 1) . For example, up-regulation of VDAC1 expression was observed in three different acute lymphoblastic leukemia (ALL) cell lines (697, Sup-B15, and RS4; 11) following prednisolone treatment, an observation that can be explored for predicting eventual outcome in childhood ALL [244] . VDAC1 over-expression was observed in a cisplatin-sensitive cervix squamous cell carcinoma cell line (A431) when exposed to cisplatin, while in a cisplatin-resistant cell line (A431/Pt) the treatment resulted in down-regulation of VDAC1 [245] . Furthermore, in human malignant melanoma cells, arbutin (hydroquinone-O-beta-D-glucopyranoside), a tyrosinase inhibitor and a potential anti-cancer agent, was found to induce apoptosis by causing VDAC1 over-expression [246, 247] . Somatostatin, reported to be useful in the treatment of advanced prostate cancer, was found to up-regulate the expression of VDAC1 and VDAC2 in the LNCaP prostate cancer cell line [248] . Up-regulation of VDAC1 has been reported upon UV irradiation of apoptosis-sensitive cells [249] . In addition, ROS was found to induce up-regulation of VDAC that could be prevented by the ROS chelator, epigallocatechin [165] . The induction of VDAC1 over-expression and increase in cellular Ca 2+ levels by cisplatin is presented in Fig. 5 .
Importantly, the causal relationship between VDAC1 expression levels and sensitivity to various treatments was emphasized in several studies ( Table 2 ). Melanoma cell lines that were relatively resistant to apoptosis induction by oblimersen sodium (G3139), an anti-sense oligonucleotide that directly interacts with VDAC to reduce its channel activity and evaluated as a possible treatment for several types of cancer [250] , were found to express lower levels of VDAC1 than did G3139sensitive melanoma 518A2 and other cell lines [250] . Similarly, reducing VDAC1 expression by siRNA efficiently prevented cisplatin-induced apoptosis and Bax activation in NSCLC [187] , and inhibited seleniteinduced PTP opening in HeLa cells [251] . The anti-cancer activity of furanonaphthoquinones (FNQs) was increased upon VDAC1 overexpression and decreased upon silencing of VDAC1 expression by siRNA [163, 252] . Recently, it was also shown that over-expression of VDAC1 sensitized carcinoma cells to apoptosis induced by cisplatin, mechlorethamine, and its derivative, melphalan [253] . Thus, following apoptosis induction by various agents, VDAC1 over-expression was observed. This, together with the correlation between drug efficacy and VDAC1 expression level, all suggest that the activities of numerous anti-cancer drugs and treatments are mediated via regulating VDAC1 expression levels.
Recently, based on the findings that several cancer drugs and treatments that act by inducing apoptosis lead to up-regulation of VDAC1 expression levels [244] [245] [246] [247] [248] 254] , an additional mode of action for apoptosis stimulus involving increased expression of VDAC1 was proposed [223] . Moreover, it has been argued that apoptosis-inducing agents act by increasing [Ca 2+ ]i and that this in turn leads to an upregulation of VDAC1 expression. This is followed by VDAC1 oligomerization, Cyto c release and finally, cell death [223] (Fig. 5) .
Although different apoptosis inducers elicit cell death via different mechanisms, all induce VDAC1 over-expression in Ca 2+ -dependent manner [223] , raising the possibility that elevating [Ca 2+ ]i represents a common mechanism for the various apoptosis stimuli, subsequently leading to elevation in VDAC1 expression. This new mechanism of pro-apoptotic drug action, namely enhancement of VDAC1 expression, provides a platform for developing a new class of anti-cancer drugs.
ER-mitochondria Ca 2+ transport, VDAC and apoptosis
Ca 2+ originating from the ER has been shown to be a potent deathinducing signal [255] . The interplay between ER and mitochondria mediated Ca 2+ signaling is a determinant of cellular fate through the control of apoptosis and autophagy [256] . Release of Ca 2+ from the ER via inositol-1,4,5-trisphosphate receptors (IP 3 Rs) has been observed in models of apoptosis and has been implicated directly in mitochondrial . This model suggests that apoptosis induction by a given stimulus causes an increase in intracellular Ca 2+ levels, leading to enhanced VDAC1 expression. The increase in VDAC1 expression shifts the equilibrium towards the VDAC1 oligomeric state, allowing for Cyto c release from the inner mitochondria space, leading to apoptotic cell death. When VDAC1 is over-expressed by transfection (b), no change in intracellular Ca 2+ level was observed [223] , suggesting that Ca 2+ is required for induction of VDAC1 over-expression and not for the subsequent steps leading to VDAC1 oligomerization, Cyto c release and finally, apoptotic cell death. Ca 2+ -induced VDAC1 expression may result from activating the VDAC1 promoter directly or by stimulating the activity of transcription factors (c).
Ca 2+ overload [257] . In this mitochondria-ER calcium-signaling cascade, IP 3 R and VDAC were identified as two important actors in the transmission of Ca 2+ signals between the ER and mitochondria [11, 40, 118, 258] . Transient expression of VDAC enhanced the amplitude of agonist-dependent increases in mitochondrial matrix Ca 2+ concentration by allowing the fast diffusion of Ca 2+ from ER release sites to the inner mitochondrial membrane [118] . The specific sites of physical association between the ER and mitochondria, known as mitochondria associated membranes (MAMs), include VDAC among the proteins present at these junctions [259] . The mitochondrial chaperone glucose-regulated protein 75 (grp75) has been proposed to mediate the molecular interaction of VDAC1 with the ER Ca 2+ release channel, IP 3 R, and that a chaperone-mediated conformational coupling of the proteins enables better transfer of the Ca 2+ ions from the ER to the mitochondria [260] . It was reported that in a cell-free system containing purified mitochondria, ER vesicles, IP 3 R, and VDAC1, PTP activity was identified as being involved in the ERtriggered pro-apoptotic mitochondrial membrane permeabilization process [258] . It has been recently established that VDAC1 (but not isoforms 2 or 3) selectively interacts with IP 3 Rs and is preferentially involved in the transmission of low amplitude apoptotic Ca 2+ signals to mitochondria [261] . The involvement of VDAC1 in ER-mitochondria Ca 2+ cross-talk places VDAC1 at a crucial position on the route transferring Ca 2+ signals from the ER to mitochondria, and thus couples ER and mitochondrial functions [261] . The emerging role of dysregulated mitochondrial Ca 2+ homeostasis in tumorigenesis has also received increasing attention [262] [263] [264] [265] . The reduction of mitochondrial Ca 2+ uptake in cancer cells can decrease activation of the mitochondrial intrinsic apoptosis pathway, and thus favors cancer cell survival and tumor metastasis [266] . It has been demonstrated that the release of Ca 2+ from ER stores induced mitochondrial Ca 2+ accumulation and triggered cell death in human cervix and colon carcinoma cell lines [258] . ER stress also induced mitochondrial membrane permeability that is regulated by members of the Bcl-2 family of proteins [124] that also interact with VDAC1 [192, 197] .
Reprogramming energy metabolism in cancer and the Warburg effect
Tumor cells thrive in environments that would be hostile to their normal counterparts. Survival depends on the selection of cells that harbor modifications of gene regulation that shifts the balance between the cell cycle and apoptosis and/or that involve plasticity of the metabolic machinery. Metabolism and cell growth are two cellular processes that are tightly linked and regulated [267] . In addition, tumor cells maintain high ATP/ADP as well as NADH/NAD + ratios, so to assure that ATP levels are never limited as ATP depletion would present an unsustainable metabolic stress for tumor cells, being associated with necrotic death in some cell types [268] .
In recent years, evidence has accumulated indicating a correlation between alterations in metabolism and cancer. It is well known that cancer cells undergo significant metabolic adaptations corresponding to adjustments in energy metabolism so as to fuel cell growth and division [269] [270] [271] . The classic bioenergetics phenotype of cancer cells usually displays enhanced aerobic glycolysis, providing precursors for the synthesis of lipids, proteins and DNA and a new redox balance. Whereas normal cells produce energy by a low rate of glycolysis followed by oxidation of pyruvate in mitochondria, malignant cancer cells typically display high rates of glycolysis even when fully oxygenated, an observation termed aerobic glycolysis [269] . Cancer cells are, moreover, subject to suppressed mitochondrial respiration, despite the fact that glycolysis is a less energy-efficient pathway, a phenomenon known as the Warburg effect [269] [270] [271] . To increase glycolysis, cancer cells upregulate the transcription of genes involved in the glycolytic pathway (i.e., glucose transporters, and glycolytic enzymes). Cancer cells actually use a combination of both glycolysis and mitochondrial respiration to produce energy, and may vary in regard to the preferential use of these pathways, being in some cases either more glycolytic/less oxidative or less glycolytic/more oxidative, depending on the prevalent normoxic or hypoxic environmental conditions and their capacities to express adequate levels of oncogenes and tumor suppressor gene products for cell growth [272] [273] [274] . Shifting the balance between the two processes via the use of glycolytic and/or mitochondrial enzyme inhibitors could be an interesting starting point in the search for new anti-cancer agents.
The Warburg effect likely provides the vast majority of cancerous tumors with a number of benefits, such as precursors for the biosynthesis of nucleic acids, phospholipids, fatty acids, cholesterol, and porphyrins. A second advantage of the Warburg effect is likely involved in both tumor protection and invasion. Tumor cells produce lactic acid via glycolysis and transport it out of the cell, creating a layer of low pH. This is proposed to protect tumors against attacks by the immune system while causing damage to normal surrounding cells, thus preparing them for invasion. Additionally, the Warburg effect assures a longer tumor survival time if oxygen becomes limiting [270] . Moreover, the cancer-associated abnormalities in glucose metabolism enhance cellular resistance to apoptosis, with mitochondria being found to play a key role in this process [275] [276] [277] [278] [279] . Lung cancer tumors and cell lines Up-regulation Western blot Tumor and healthy tissues from the same patient were compared [421] The high glycolytic rate that is characteristic of hypoxic solid tumors is attributed to marked over-expression of mitochondrial-bound HK that is considered the rate-limiting enzyme of glycolysis [2, [280] [281] [282] . HK likely plays a key role in cell growth rate and survival of cancer cells and is probably a major factor underlying the Warburg effect [273, 281, [283] [284] [285] . The metabolic re-programming of the cancer cell includes HK interacting with VDAC1, with this interaction offering several advantages to cancer cells [2, 6] , as outlined below (see Section 8.1).
Mitochondria regulate glycolytic flux with the actions of the TCA cycle and ATP synthase to balance the energy requirements of the tumor cell with biochemical requirements for metabolites (i.e., the anaplerotic and cataplerotic pathways, respectively) or metabolite precursors that are required by the tumor [2, 281, 282, 285] . Thus, both the glycolytic pathway and other seminal metabolic pathways, like the pentose phosphate shunt, are regulated via the energy-coupling resulting from the formation of the VDAC1-bound HK complex.
Yet another link between VDAC1 and the regulation of metabolism is reflected by the regulation of HK-VDAC1 complex formation by Akt [286, 287] and glycogen synthase kinase 3 beta (GSK3β). In addition, it was shown that an increase in the amount of free cytoplasmic tubulin induced by microtubule-destabilizing agents decreased VDAC conductance and mitochondrial membrane potential (ΔΨ(m)). Tubulindependent suppression of ΔΨm was further potentiated by protein kinase A activation and GSK3β inhibition. Tubulin-dependent suppression of ΔΨm is universal for all three VDAC isoforms [16] . HK also functions as a regulator of cell viability and apoptosis by preventing the release of Cyto c from the mitochondria [2, [280] [281] [282] 288 ] (see Section 8.1).
VDAC1-interacting proteins
VDAC1 at the OMM serves as a hub protein interacting with diverse sets of cytosolic and mitochondrial proteins which, together with VDAC1, mediate the metabolic and signaling cross-talk between cytosol and mitochondria ( Fig. 6 ). Some of these interacting proteins are also highly expressed in many cancers, such as Bcl2, Bcl-xL and HK. Thus, VDAC1 provides structural and functional anchoring sites allowing the regulation of metabolic and apoptotic processes in normal and cancer cells. VDAC1 displays binding sites for glycerol kinase [289] , HK [184, 233, 243, [290] [291] [292] , creatine kinase [293] , C-Raf kinase [294] , ANT [295] , the peripheral benzodiazepine receptor (also known as TSPO, translocator protein) [296] , tubulin [297] , the dynein light chain, PBP74 (heat-shock protein peptide-binding protein 74) known also as mtHSP70/GRP75/mortalin, the ORDIC channel, glyceraldehyde 3phosphate dehydrogenase (GAPDH) [11] , actin [298] and gelsolin [299] , as well as Bcl-2 family members [181, 196, 197, 300, 301] . Interaction with apoptosis-regulating proteins, such as HK and Bcl-2 family members, make VDAC1 a key protein in apoptosis regulation [7] . Here, we focus on those VDAC1-interacting proteins showing modified levels of expression in cancer cells.
Interaction of VDAC1 with HK regulates cancer cell bioenergetics and apoptosis
HK expression and bioenergetics regulation in cancer cells
One of the signature phenotypes of highly malignant, poorly differentiated tumors is their high rate of glycolysis, leading to enhanced lactate generation [302] . This property is frequently dependent on the marked over-expression of VDAC1-bound HK in cancer cells [152, 282, 303, 304] . HK thus lies at the apex of the glycolytic pathway that provides the metabolic intermediates required by the biosynthetic pathways on which a transformed cell places heavy demand [283, 285] . Due to a higher rate of glycolysis in the tumor cell, the glucose consumption of cancer cells is greater than that of non-malignant cells. As such, inhibition of glycolytic energy production could provide a framework for the discovery of new anti-cancer compounds.
HK catalyzes the rate-limiting step in glycolysis, namely the ATPdependent phosphorylation of glucose to glucose-6-phosphate (G-6-P). The mitochondria-bound isoforms HK-I and -II were found to be overexpressed in many cancers, including colon, prostate, lymphoma, glioma, gastric adenomas, carcinomas and breast cancers [152, 283] . The elevated levels of mitochondria-bound HK in cancer cells is suggested to play a pivotal role in promoting cell growth and survival in rapidly growing, highly glycolytic tumors and in protecting against mitochondria-mediated cell death [281] . As presented below, the association/dissociation of HK with/from VDAC1 and the switching of VDAC1 between an 'open' and a 'closed' state regulate the metabolic cross-talk between mitochondria and the cytosol [2, 181] . This control is important for maintaining the mitochondrial respiration and glycolysis equilibrium at the heart of the energetic and metabolic homeostasis of the cancer cell.
VDAC1 is the mitochondrial-binding site of HK
The interaction of HK with the mitochondria, and specifically with VDAC1, has shifted our view of HK as predominantly fulfilling a metabolic role to one of regulating the apoptotic responsiveness of the cell, making the VDAC1-HK complex a target for therapeutic purposes [93, 181, 184, 233, 243, 288, [290] [291] [292] 305] . The interaction between HK-I and VDAC1 was first demonstrated in a reconstituted system where HK-I decreased the channel conductance of VDAC1, an effect that was reversed by G-6-P, shown to detach HK from isolated mitochondria [243] (Fig. 7) . The interaction between HK-I and VDAC1 was again demonstrated by co-immunoprecipitation [155] . The co-localization of HK-I with each of the three isoforms of VDAC1 was demonstrated using two-color stimulated emission depletion (STED) microscopy [306] . HK-I-VDAC1 interaction could be abrogated upon mutagenesis of a single VDAC1 residue (Glu73, Glu202 or Glu65), resulting in the elimination of HK-mediated protection against apoptosis and channel closure [121, 184] . N-terminally-truncated VDAC1 is incapable of binding HK [62] or Bcl-xL [196] . Moreover, when the N-terminal region α-helix structure in VDAC1 was perturbed, binding of HK was reduced [49] . It was proposed that the N-terminal region of HK-I is inserted into the channel pore, where it interacts with the N-terminal region of VDAC1 [307] . It should be noted that there is strong residue conservation between the HK-I and HK-II N-termini, and that such conservation is not shared by the other two non-bound mitochondrial HK isoforms, HK-III and HK-IV.
Finally, the VDAC1-HK interaction was shown to be regulated by phosphorylation as occurs when glycogen synthase kinase 3β (GSK3β) is up-regulated [292] in a process mediated via protein kinase C (PKC) [93] , as well as in response to the cholesterol content of the OMM [93] .
HK protection against cell death is mediated via interaction with VDAC1
Both in vitro and in vivo studies have shown that elevated levels of mitochondria-bound HK in cancer cells also protect against mitochondria-mediated apoptosis via direct interaction with VDAC1. Mitochondrially-associated HK has been shown to protect HeLa and HEK cells from entering apoptosis [62, 121, 152, 184] . This protection was related to a blockade of the interaction of the pro-apoptotic protein Bax with VDAC1 [152] . Moreover, over-expression of HK-I or HK-II in tumor-derived cell lines suppressed STS-induced Cyto c release and apoptosis [121, 243, 290] . A decrease in apoptosis and an increase in cell proliferation have also been reported to be induced by HK-II expression in the NIH-3 T3 [308] and rat 1a cell lines [303] . Importantly, mutagenesis studies revealed that single mutations or N-terminal truncation Fig. 7 . Hexokinase binding to mitochondria and to bilayer-reconstituted VDAC1 that reduce its channel conductance. A. To demonstrate VDAC1-mediated HK-I binding to mitochondria, a HK-I-GFP fusion protein was expressed in HeLa cells. Confocal fluorescence microscopy shows that HK-I-GFP fluorescence (left panel) is punctuated, as expected for mitochondrial distribution, and is co-localized with the mitochondrial marker, MitoTracker (right panel). Images show representative microscopic fields from one of three similar experiments. Scale bar = 5 μm. B. HK-II was cloned and expressed in Escherichia coli and purified using Ni-NTA. VDAC1 was reconstituted into a PLB (as described in Fig. 2) , and channel currents through VDAC1, in response to voltage steps: 0 to 10 mV (I) or 0 to 40 mV (II), were recorded before and after the addition of human HK-II (2 μg/ml). The dashed lines indicate zero current. C. The effect of human HK-II on VDAC1 as a function of voltage, from 60 to −60 mV. The average steady-state conductance at a given voltage was normalized to the conductance recorded at 10 mV. Recordings were taken before (•) and after (○) the addition of HK-II. in VDAC1 prevented HK-I-mediated protection against apoptosis and channel closure in a reconstituted membrane system [62, 121, 184, 288] . In addition, binding of HK-II to mitochondria inhibited Bax-induced Cyto c release and apoptosis [305] . Finally, VDAC1-based peptides were found to interact with purified HK and when expressed in cells overexpressing HK, prevented the anti-apoptotic activity of HK [290] .
The interaction of HK with VDAC1 offers advantages to cancer cells
Several mechanisms by which HK binding to VDAC1 protects against apoptosis and promotes cell survival can be considered. These include controlling energy and metabolic homeostasis, as well as preventing VDAC1-mediated Cyto c release and shielding VDAC1 from proapoptotic factor binding, thus offering the tumor cell protection from cell death in a synergistic manner. At the same time, disruption of this interaction provide a strategy to interfere with cancer cell growth (see Section 10.2.2). The advantages to cancer cells of HK binding to VDAC1 include:
i. Production and access to energy and metabolites -HK bound to VDAC1 provides cells with metabolic advantages that allow for enhanced cell growth [285] . Anchoring of HK to VDAC1 offers the enzyme direct access to mitochondrial sources of ATP and greater affinity for Mg 2+ -ATP [18, 309] . HK bound to the cytosolic face of VDAC1 acts as a gate, regulating the traffic of various metabolites through the VDAC1 channel [243] . In addition, VDAC1-bound HK is less sensitive to inhibition by its product, G-6-P [243] , thus avoiding product inhibition. The HK-VDAC1 interaction thus increases energy and metabolite production of the high energy-demanding cancer cells, allowing for maintenance of a high glycolytic flux rate in tumors [243, 310] . ii. VDAC1-bound HK acts as an anti-apoptotic protein -Accumulated evidence demonstrated that HK-I and HK-II also function as antiapoptotic proteins when bound to VDAC1, while their detachment enabled activation of apoptosis [93, 181, 184, 233, 243, 288, [290] [291] [292] 305] . Disruption of HK binding to VDAC1 by mutation in VDAC1 or by addition of VDAC1-based peptides diminished HK anti-apoptotic activity [290] . HK interaction with VDAC1 protected against activation of apoptosis by Bax or Bak [93, 286, 305] . The detachment of HK-II from the mitochondria was found to markedly potentiate the onset of caspase 2-induced mitochondrial damage [311] . iii. Regulation of ROS production by HK -ROS act as second messengers in cell signaling and are essential for multiple biological processes in normal cells. However, ROS can also provoke damage to multiple cellular organelles and processes [312] . ROS production is usually increased in cancer cells due to oncogene activation [313] . Mitochondria-associated HK was shown to reduce mitochondrial ROS generation [151] , with HK-I and HK-II reducing intracellular levels of ROS [149] . Moreover, expression of both HK-I and HK-II was found to protect against oxidant-induced cell death [150, 152] . Thus, detachment of HK from VDAC1 could lead to increased ROS generation and release to the cytoplasm, thereby activating cell death. iv. Stabilization of both HK and VDAC1 -VDAC1, containing an odd number of β-strands, presents conformational intrinsic instability within the first four β-strands (β1-4), relative to other VDAC1 regions [46] . In silico studies of the VDAC1-HK-I interaction predicts that both proteins attain a more stable state through proteinprotein interactions [307] . It is proposed that upon binding with the N-terminal helix of HK-I, VDAC1 acquires higher stability via the formation of a network of chemical bonds both due to direct protein-protein contacts and to hydrogen bonds mediated by an ATP molecule and a Mg 2+ ion [307] . Stabilization of VDAC1 (overexpressed in cancers; Section 10.1) by HK is important for VDAC1 to fulfill its function in energy and metabolism homeostasis. v. Increased synthesis and uptake of cholesterol -Cancer cells have been shown to exhibit a 2-10-fold increase in mitochondrial cholesterol content, in comparison to liver mitochondria [77] . It has been proposed that the increased binding of HK to the mitochondria of cancer cells may play a role in mediating increased synthesis and uptake of cholesterol into the mitochondria of cancer cells [93] . It has been shown that disruption of VDAC1-hexokinase binding in cancer cells resulted in a decrease of cholesterol content of the OMM and increased sensitivity to mitochondrial matrix swelling, suggesting that VDAC1 influences cholesterol distribution in the OMM (see Section 3.2), and may impact oxidative phosphorylation and apoptosis sensitivity in cancer cells [83] .
Many attempts to target glycolysis via inhibiting HK, including via treatment with 2-deoxyglucose (2-DG), 3-bromopyruvate (3-BP), an alkylating reagent that reacts with the free SH groups of cysteine residues in certain proteins that also targets GAPDH, or lonidamine, a derivate of indazole-3-carboxylic acid [314] . 3-BP has been proposed to covalent modify HK-II, leading to its dissociation from mitochondria and apoptosis induction [315] . However, the use of glycolytic inhibitors for cancer treatment raises potential concerns and challenges as these compounds are not very potent and because certain normal tissues, including brain, retinae, and testis, use glucose as the main energy source [314] . On the other hand, the VDAC1-HK interaction was identified as a promising target for concomitant anti-cancer therapy [314] .
Interaction of VDAC1 with Bcl-2 family members
One of the hallmarks of cancer cells is their resistance to apoptosis. This can be acquired through a variety of strategies, including quenching of the mitochondrial apoptotic pathway by over-expression of anti-apoptotic proteins of the Bcl-2 family. This in turn contributes to tumor initiation, disease progression, drug resistance [300, 301, [316] [317] [318] [319] and cellular responses to anti-cancer treatments [320, 321] . The Bcl-2 family of proteins function as central regulators of apoptosis in mammals and include proteins that both up-or down-regulate apoptosis [320, 321] . The family comprises close to 25 pro-apoptotic (e.g. Bid, Bax, Bim and Bak) or anti-apoptotic (e.g. Bcl-2 and Bcl-x L ) members. All of these proteins are characterized by the presence of Bcl2 homology (BH) domains and are classified by sequence homology based on the presence of up to four α-helical domains, termed Bcl-2 homology (BH)1 to 4 domains [300, 321] . These can be further sub-divided into three main groups, based on the BH domain(s) they contain and their function. Anti-apoptotic family members, such as Bcl-2, Bcl-xL, Mcl-1, Blf1 and A1, contain four BH domains (BH1-4), whereas some pro-apoptotic family member proteins, such as Bax and Bak, contain three BH domains (BH1-3). Others family members, such as Bid, Bim, Bad, Bik, Noxa, PUMA and Bmf, contain only one BH3 domain [175, 300, [321] [322] [323] [324] [325] [326] .
The mechanisms by which Bcl-2 family proteins regulate apoptosis are still not fully understood, although it is well established that their activities are mediated via interactions with mitochondria and by controlling OMM permeability [327] . Accumulated evidence indicates that the regulation of apoptosis by pro-and anti-apoptotic members of the Bcl-2 family is mediated via their interactions with VDAC1 [62, 187, 195, 197, 290, [328] [329] [330] . VDAC1 has been shown to interact with Bax/Bak, Bcl-2 [197] , Bcl-xL [47, 192, [195] [196] [197] 328, 330, 331] and with Bax and Bim [220, 328] . It was also reported that both proapoptotic Bax and anti-apoptotic Bcl-xL interact simultaneously with the putative loop regions of human VDAC1 to create a tertiary complex [234, 332] . Bax was also found to increase VDAC1 conductance [219] . Additionally, Bcl-2 and Bcl-xL block As 2 O 3 -induced VDAC1 dimerization [183] . BH4 oligopeptides derived from Bcl-2 and Bcl-xL are alone able to inhibit both VDAC1 activity in liposomes, even in the presence of pro-apoptotic protein such as Bax, and prevent ΔΨ(m) loss in isolated mitochondria [330] . Recently, an interaction of Bcl-2 and Bcl-xL with VDAC1 and the subsequent reduction of the channel conductance of native but not mutated reconstituted VDAC1 was shown [196, 197] . The proteins also protected against apoptosis in cells expressing native but not mutated VDAC1 [196, 197] . Moreover, it was shown that Bcl-xL can modify the oligomerization status of VDAC1 by shifting the equilibrium from the trimeric to the dimeric state [47, 195] .
In contrast, the multi-BH domain-containing pro-apoptotic members Bax and Bak are the essential gateways for OMM permeability and it has been suggested that both physically interact with VDAC1 to yield a complex with permeability 4-10 times larger than that of VDAC1 alone [194, 228] . Consequently, recombinant pro-apoptotic proteins Bax and Bak accelerate the opening of VDAC1 channels in liposomes and induce Cyto c release. Bcl-xL and anti-VDAC1 antibodies prevent this release [182] . Bax and VDAC1 reconstituted into liposomes were shown to form a channel with higher conductance than VDAC1 alone, with this increase being prevented by Bcl-xL [194] . In agreement, VDAC1-deficient mitochondria from mutant yeast did not exhibit Bax/ Bak-induced loss in membrane potential or Cyto c release [192] . In addition, cisplatin-induced activation of Bax was inhibited in VDAC1depleted cells [187, 192] , suggesting that VDAC1 is involved in Bax-mediated apoptosis. A novel human BH3-only protein (designated as Bop), which induces apoptosis in a BH3 domain-dependent manner, mainly localized to mitochondria where its BH3 domain contacts the loop regions of VDAC1 in the OMM. Purified Bop induced the loss of ΔΨ(m) and the release of Cyto c. Bop uses its BH3 domain to contact pro-survival Bcl-2 family members (Bcl-2, Bcl-xL, Mcl-1, A1 and Bcl-w) which could inhibit Bop-induced apoptosis [333] . In addition, Bax-VDAC interaction was also implied by the curcumin-induced mitochondrial translocation of Bax, which was blocked by DIDS [334] , shown to interact with VDAC and reduce its channel conductance [39] . The requirement of VDAC2 for the pro-apoptotic activity of Bax has also been demonstrated [335] . However, it was concluded that VDAC2 acts to physically restrain BAK in the OMM in non-stimulated viable cells [336] . It was also demonstrated that Bcl-x(S) over-expression resulted in disruption of the VDAC2-Bak interaction leading to release of Bak [36] . Bak was shown to incorporate into a VDAC2-Mtx1-Mtx2 multiprotein complex in resting and dying cells. Upon TNF-induced apoptosis, Bak interacts with Mtx1 and promotes apoptosis [337] . In addition, the death signals that displace VDAC2 from Bak were found to promote Bak oligomerization and apoptosis [336] . Anti-VDAC antibodies inhibited Bax-and Bim-induced release of Cyto c [182] , whereas Bid (but not Bax) was shown to modify the conductance of bilayerreconstituted VDAC channels [338] . In addition, As 2 O 3 -induced VDAC dimerization in IM-9, a multiple myeloma cell line, was blocked by supposed VDAC interaction with Bcl-2 and Bcl-xL [183] .
Those VDAC1 domains involved in the interaction with Bcl-2 and Bcl-Xl to confer anti-apoptotic activity were identified by site-directed mutagenesis [196] . VDAC1-based peptides corresponding to the VDAC1 N-terminal region and to other selected sequences interact specifically, in a concentration-and time-dependent manner, with Bcl-2 and Bcl-xL to prevent their anti-apoptotic activities [62, 197, 234, 288, 290] . These results indicate that VDAC1 binds Bcl-2 family proteins to regulate their effects on apoptosis and hence, interfering with such interactions could facilitate apoptosis induction and enhance the therapeutic effect of chemotherapeutic agents.
Translocator protein (TSPO) and VDAC1
Translocator protein, also known as the peripheral benzodiazepine receptor, is a highly hydrophobic 18 kDa protein mainly found in the OMM [296, 339] . TSPO is a multi-functional protein associated with the regulation of cholesterol transport, steroidogenesis, porphyrin transport, heme synthesis, apoptosis and cell proliferation [340] . TSPO is over-expressed in different types of tumors and cancer cell lines, such as CLL, breast, colorectal, prostate, ovarian, glioma and hepatocarcinoma cancer cells, and its involvement in the modulation of cell proliferation and tumorigenesis has been shown [341, 342] . Moreover, increased TSPO expression was correlated with an increased aggressive cancer cell phenotype [341, 343] . TSPO expression, nuclear localization, and TSPO-mediated cholesterol transport into the nucleus are involved in breast cancer cell proliferation and aggressive phenotype expression, with TSPO expression correlating with advancing stages of this malignancy [344] . TSPO is mainly found on the OMM [340, 345] , where it is closely associated with VDAC [346] . It has been hypothesized that the close association of TSPO with VDAC allows ROS generated via TSPO to affect VDAC [296, 347] . In addition, the reported grouping of TSPO molecules around VDAC, potentially reflecting TSPO polymerization [296, 348] , could enhance the concentration of ROS generated by TSPO in the proximity of VDAC, leading to apoptosis induction [296, 349, 350] . In addition, over-expression of TSPO inhibits VDAC1 expression, while the silencing of TSPO increases VDAC1 expression in endothelial cells [351] . PTP opening is regulated by different TSPO ligands, such as the agonist Ro5-4864 and the antagonist PK11195, as well as by the endogenous ligand protoporphyrin IX [352, 353] . PK11195 induced mitochondrial depolarization and Cyto c release in primary CLL cells, with such PK11195-induced apoptosis being inhibited by DIDS, also shown to interact with VDAC, suggesting a possible interaction between TSPO and VDAC [346, 350, 353] . However, the pro-apoptotic effects of PK11195 and Ro5-4864 were attributed to their interaction with low-affinity binding sites not directly related to VDAC [296] .
Interaction of VDAC1 with and regulation by cytoskeletal proteins
In cancer, morphogenic changes are required for high proliferative rates, the acquisition of inappropriate migratory patterns, and invasive characteristics [354] . Alterations in the dynamics of the actin and tubulin components of the cytoskeleton are well-known consequences of signaling and the triggering of responses like apoptosis [355, 356] . Mitochondria are dynamic organelles that actively travel along the cytoskeleton within the cell. As such, many cytoskeleton-related proteins interact with mitochondria, often via VDAC1.
Gelsolin (Gsn) is a Ca 2+ -dependent actin-regulatory protein that modulates actin assembly and disassembly [357] . It is a cytoplasmic protein yet is found in the mitochondrial fraction of cells [358] . Human Gsn has anti-apoptotic activity, whereas mouse Gsn exerts either pro-apoptotic or anti-apoptotic activity, depending on the cell type [299] . The anti-apoptotic activity of hGsn depends on its Cterminal half (G5 segment) that prevents Cyto c release in isolated mitochondria. hGsn and the G5 segment inhibit the channel activity of VDAC1 and Cyto c release from liposomes through direct binding to VDAC1 in a Ca 2+ -dependent manner [299, 359] . On the other hand, expression of an N-terminally-cleaved Gsn product resulted in apoptosis [360] . Gsn is a caspase 3 substrate and the cleaved fragment has been implicated as an effector of apoptosis [361] .
Adseverin or scinderin is a member of the calcium-regulated gelsolin super-family affecting the actin polymeric state. Adseverin shares 60% identity with gelsolin but lacks the C-terminal extension [362] . Adseverin predominantly co-localizes with F-actin in bovine adrenal medulla chromaffin cells, whereas gelsolin is diffusely localized in such cells [363] . Adseverin is over-expressed in a cisplatin-resistant human bladder cancer cell line (HT1376-CisR), with the increase being more prominent in the mitochondrial than in the cytosolic fraction [364] . Adseverin silencing by siRNA significantly reduced cell proliferation, with mitochondria-mediated apoptosis resulting in HT1376-CisR cells. Immunoprecipitation analysis revealed that adseverin interacts with VDAC1 in mitochondria and it was suggested that in CDDP-resistant cells, the VDAC-adseverin interaction inhibited mitochondria-mediated apoptosis [364] .
Tubulin, a constituent of microtubules, is known to positionally stabilize organelles, such as mitochondria, and to participate in contacts between the ER and mitochondria. Within this framework, specific association of VDAC1 with tubulin was shown by coimmunoprecipitation [365] and by tubulin-induced VDAC1 closure [297] . VDAC1 permeability is proposed to be controlled by dimeric tubulin, whereby the negatively charged C-terminus of tubulin penetrates into the positively charged VDAC1 pore, reducing its channel conductance [297, 356] . Moreover, it was suggested that tubulin-dependent closure of VDAC is important as a physiological process that sustains the Warburg effect [356] , with tubulin isoforms such as βIII-tubulin playing a role in cellular adaptation to metabolic glucose deprivation [366] . It was proposed that tubulin, VDAC1 and mitochondrial creatine kinase (MtCK) are all members of a super-complex that is structurally and functionally coupled to the ATP synthasome [367] . In a cellular model of cardiomyocyte physiology, this complex presents a distinct composition, where tubulin is replaced by HK and MtCK is absent, thereby infusing mitochondrially generated ATP into the glycolytic pathway and thus contributing to the Warburg effect [367] .
Recently, it was suggested that VDAC1 and VDAC2 are most inhibited by cytoplasmic free tubulin and that such interactions limit mitochondrial metabolism in HepG2 cells, contributing to the Warburg effect, with erastin reversing the tubulin-VDAC interaction [368] . MtCK coupled to the ATP synthasome and to VDAC, as controlled by tubulin βII, provides functional compartmentation of ATP in mitochondria and energy channeling into the cytoplasm via the phosphotransfer network. Tubulin is over-expressed in mitochondria of different human cancers and non-neoplastic cell lines and could play a role in the regulation of the mPTP [365] . βIII-tubulin expression is increased in mitochondria of tumor cells and rescued tumor cells from cell death signals triggered by DNA-targeting compounds, such as cisplatin, doxorubicin, and etoposide [369, 370] .
G-actin directly and selectively binds to VDAC in yeast, as demonstrated by surface plasmon resonance [371] . Moreover, the monomeric form of G-actin could modulate gating of the Neurospora crassa VDAC channel by reducing its conductance [298] .
Finally, microtubule-associated protein 2 (MAP2) was shown to bind VDAC by affinity chromatography [372] .
Other proteins interacting with VDAC1
MAVS
The mitochondrial anti-viral signaling protein, also known as IPS-1, VISA, or Cardif [373] and localized in the OMM, participates in host defense against viral infection by inducing interferon type I (IFN-I) production [374] . MAVS induced caspase-dependent and IFN-independent apoptosis in response to viral infection, indicating that mitochondriallocated MAVS might play an important role in virus-triggered apoptosis induction, independent of its role in innate immunity [375] . Recently, it was demonstrated that mitochondrial-located MAVS mediates its proapoptotic activity by associating with VDAC1 and modulates VDAC1 protein stability via the ubiquitin-proteasome pathway [376] . MAVS knockout mouse embryonic fibroblasts (MEFs) displayed reduced VDAC1 expression, while ectopic expression of MAVS resulted in VDAC1 up-regulation and promoted apoptotic cell death [376] .
SOD1
Superoxide dismutase 1 (SOD1) is a predominantly cytosolic protein, with mutant SOD1 being present mostly in fractions enriched for mitochondria [377] [378] [379] . Mutant SOD1 associated with amyotrophic lateral sclerosis (ALS) bound to bilayer-reconstituted VDAC1 and inhibited its channel conductance [380] . Mutant SOD1 interacted with Bcl2 protein and altered the normal interaction between Bcl-2 and VDAC1, thus reducing OMM permeability [381] .
eNOS
Endothelial NO synthase was also found to bind VDAC1. Such interaction amplified eNOS activity in an intracellular Ca 2+ -mediated manner [382] . These findings suggest that the interaction between VDAC and eNOS may be important for regulating eNOS activity and modulation of VDAC [382] .
Other proteins
Several proteins were shown or proposed to directly interact with VDAC1, These include Nek1 (NIMA-related protein kinase 1) [249, 383] , aldolase [11] , Tctex-1/DYNLT1 (dynein light chain) [384] , MAP2 [372] , CRYAB (α-crystallin B) [385] and α-synuclein [386] .
In summary, VDAC1 serves as a central hub for responses to cellular signaling as mediated by its interaction with over a dozen proteins (Fig. 6 ). This may explain why VDAC1 is a highly conserved protein in both the entire population and in patient somatic cells (see Section 10). This finding indicates that VDAC1 is under strong purifying selection, meaning that mutation of the encoding gene is less tolerated than are mutations in most other genes.
Alterations in VDAC1 expression or sequence in cancers
VDAC1 expression in cancer cell lines and tumors
Human tumors are riddled with genomic alterations that include not only mutations that disrupt a wide spectrum of genes but also those that affect proteins expression levels. While deep sequencing methods are widely accepted as a means to detect and analyze cancer biomarkers [387] , other cancer-associated changes are not mutation-related but rather appear as alterations in the expression or post-translational modification of marker proteins [388] . Histological indicators of cellular morphology have also been used for diagnostic and prognostic assessment of cancer samples, especially solid tumors. While these parameters are valuable for providing information about tumor differentiation, aggressiveness, and risk of recurrence, they are limited in their ability to predict individual differences in clinical outcomes [389] . Thus, appropriate biomarkers should be identified and explored as early markers of the disease, as indicators of the disease state, and as predictive and prognostic gauges of treatment effectiveness.
VDAC1 is over-expressed in many cancer types. This is not surprising in light of its well-established functions in cell metabolism and energy production, both important systems for high energy-demanding cancer cells. As presented above, VDAC1 is the main transporter of ATP, as well as other metabolites and ions through the OMM. VDAC1 mediates cholesterol transport and distribution in the mitochondrial membrane, with cancer cells exhibiting much higher cholesterol levels than do healthy cells. Over-expressed VDAC1 presents anchoring sites for over-expressed HK, allowing direct transport of mitochondrial ATP for glucose phosphorylation, thereby increasing the glycolytic rate, a characteristic of cancer cells (i.e., the Warburg effect) (see Section 7) . Finally, over-expressed VDAC1 offers binding sites for Bcl2 and Bcl-xL, allowing these proteins to mediate their anti-apoptotic activities (see Section 8.2) .
Several studies have demonstrated remarkable differences in the expression of VDAC between cancer cell lines and tumors and normal tissues. Similarly, the transcript levels of the three VDAC isoforms were significantly higher in AH130 than in normal liver cells. In addition, higher VDAC1 levels were associated with sarcomatous alterations of primary malignancies of the biliary tract [390] . Mass spectrometry and Western blot analysis of gastric cancer cells identified altered expression levels of nine apoptosis-related proteins, including VDAC1 [391] . VDAC1 expression in several cancer cell lines was higher than in a control fibroblast cell line [163, 252] . Non-small cell lung cancer (NSCLC) cells specifically exhibited high VDAC1 expression levels. In this respect, immunoblot analysis of lung cancer tissue revealed that a C-terminally truncated VDAC1 (VDAC1-ΔC) was present in tumor cells exposed to hypoxia [392] . This hypoxia-induced form of VDAC1 was detected in tissues of 50% of 46 patients with lung cancer [392] and was shown to be associated with resistance to chemotherapy-induced apoptosis in some cancer cell lines [392] .
The over-expression of VDAC1 in a panel of cancer types was clearly demonstrated using cancer tissue arrays and immunhistochemistry (Fig. 8A,B ). VDAC1 expression levels were found to be substantially higher in different cancer types, relative to the non-cancer counterpart tissues. Among these were thyroid, lung, cervix, ovary, pancrease, melanoma, glioblastoma cancers. The over-expression of VDAC1 in cancer cells was further demonstrated by comparing VDAC1 levels in lung tissue samples taken from healthy and tumor-containing areas of the same patient (Fig. 8C ). Western blot analysis of peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients showed several-fold increase in VDAC1 expression levels, as compared to the same cells from healthy donors (Fig. 8D) . The results clearly demonstrated that in all tissue samples collected from eleven patients, VDAC1 was over-expressed in the tumor tissue at levels up to over 8-fold higher than in healthy tissue.
In addition, in several melanoma and prostate cancer cell lines, a correlation between levels of VDAC1 expression and induction of Cyto c release by G3139 was demonstrated [250] . Proteomic analysis of aging-related proteins in human normal colon epithelial tissues showed significant up-regulation of nineteen proteins, including VDAC1 and VDAC2 [393] . It has also been shown that CD45 expression is accompanied by elevated VDAC1 expression in myeloma cells sensitized to a diverse set of apoptotic stimuli acting via mitochondrial pathways [394] . In addition, VDAC1 expression was correlated with tumor progression and sensitivity to chemotherapy [395, 396] , whereas gene expression analysis of NSCLC patients revealed VDAC1 expression levels as a predictor of poor outcome [397] . Finally, proteomic analysis of primary lung adenocarcinoma tumors showed a direct correlation between VDAC1 up-regulation and poor prognosis [396] . Thus, VDAC1 expression levels can be used as a molecular biomarker to forecast cancer development and treatment efficacy and potentially enable early diagnosis, as well as provide prognostic and treatment guidance.
In accord with its central role in cell metabolism, enhanced VDAC1 expression is advantageous to cancer cells. However, as VDAC1 is involved in apoptosis, and, as previously demonstrated, increased VDAC1 expression leads to apoptotic cell death (see Section 5.1), augmentation of VDAC1 levels can be turned against cancer cells. In cancer cells, over-expressed anti-apoptotic proteins (i.e. Bcl2, Bcl-xL and HK) all interact with VDAC1 to prevent its pro-apoptotic activity [62, 121, 184, 196, 197, 290] . However, when association of these proteins with VDAC is interrupted, such as by VDAC1-based peptides [62, 121, 184, 196, 197, 290] , over-expressed VDAC1 becomes a proapoptotic agent. Thus, VDAC1 over-expression in cancer functions as double-edged sword, on the one hand providing many advantages to the cancer cell yet once its regulation by anti-apoptotic proteins is disrupted, the high levels of VDAC1 encourage oligomerization of the protein (see Section 4.4) . In this case, VDAC1 displays its proapoptotic activity, leading to cell death.
VDAC1 mutations in tumors
Cancer cells accumulate in response to inherited or acquired genetic abnormalities [398, 399] . To analyze mutations in VDAC1, Gene Expression Omnibus (GEO) [400] and The Cancer Genome Atlas (TCGA) data were consulted [401] . The latter database contains information collected from a large number of cancer patients, including sequencing, gene expression, and clinical data. Analysis of germline (inherited) mutations in VDAC1 and fifty neighboring genes in colon carcinoma, rectum adenocarcinoma, serous cyst adenocarcinoma and kidney renal clear cell carcinoma patients revealed that VDAC1 showed dramatically decreased variations than seen in the other neighboring gene (Golan, Shoshan-Barmatz and Rubin, unpublished data). Modified versions of VDAC have been reported. DNA sequencing of colorectal cancer (CRC) and gastric cancer (GC) revealed a repeated VDAC1 mutation that leads to a premature stop codon (c.332delA), resulting in truncated VDAC1 missing about 60% of the C-terminal end of the protein. This Fig. 8 . VDAC1 over-expression in cancer. Immunohistochemical staining of VDAC1 was performed on tissue microarray slides obtained from Biomax US. Representative sections of cervix and lung (A) and thyroid and ovary (B) shows higher levels of VDAC1 in cancer tissues (n = 20) than in normal tissue (n = 5), with the percent of sections stained at the intensity indicated by the scale above. The slides were incubated with anti-VDAC1 antibodies diluted in 1% BSA in PBS overnight at 4°C and then with secondary antibodies diluted in 1% BSA in PBS. The slides were subsequently treated with 3'3-diaminobenzidine tetra-hydrochloride (DAB) and counter-stained with hematoxylin. Negative controls without primary antibody incubation were also performed. Sections of tissue were observed under an Olympus microscope and images were taken at 200× magnification with the same light intensity and exposure time. The images below show 3-fold magnification of the section area in the black box. C. Representative immunoblots using anti-VDAC1 antibodies of tissue lysates of healthy (H) and tumor (T) tissues each derived from the same lung of a lung cancer patient (numbered). The fold change represents the increase in VDAC1 level in the tumor in comparison to the healthy tissue, both from the same patient. D. Representative immunoblot showing VDAC1 over-expression in peripheral blood mononuclear cells (PBMCs) derived from chronic lymphocytic leukemia (CLL) patients, as compared to PBMCs from healthy donors, as probed with anti-VDAC1 and anti-β-actin antibodies. mutation did not, however, lead to significant clinicopathologic features of GC or CRC [402] .
VDAC1 interacts with over a dozen proteins [3] (see Fig. 6 ) and thus can be considered as a hub protein. Hub proteins have previously been shown to be more evolutionarily conserved than are non-hub proteins [403] . Considering the multiple functions of VDAC1 in the cell, particularly in cancer, it is not surprising that VDAC1 is highly conserved in cancers and at the population genetic level as well. These results are further supported by the finding that VDAC1 SNPs are 8.5 times less likely to alter an amino acid than are SNPs in sixteen neighboring genes. This also implies that in the human population, VDAC1 is under selection against any alteration in the encoded protein sequence. An important conclusion from these results is that VDAC1 is a highly conserved gene in the human population and even within tumors at the somatic level. These findings thus make VDAC1 as an excellent target for anti-cancer intervention as its low variability between patients reduces the chances of a genetically stratified effect and the possibility that tumors will develop resistance to VDAC1-based drugs by acquiring mutations in VDAC1.
Unraveling VDAC1-based therapies
Cancer cells do not resemble normal cells in terms of morphology or metabolic behavior [404] . Accordingly, much effort has been invested worldwide in developing anti-cancer therapies that can kill cancer cells without harming normal cells. These therapies target functional molecules that are differentially expressed in cancer and normal, nontransformed cells. For this purpose, a myriad of new small molecular weight synthetic and/or natural inhibitor compounds are being tested toward achieving selective anti-cancer clinical treatments. Small molecular weight chemicals from plants (phytochemicals) often display multi-targeted anti-cancer activities, including cell cycle arrest, inhibition of cell growth, proliferation and metastasis, and promotion of apoptosis and cell death [405] .
Small molecule drugs interacting with VDAC
Several drugs have been shown to interact with VDAC1 in manners that mediate the pro-apoptotic activities of the protein (Table 1) . These reagents include erastin, an anti-tumor agent selective for tumor cells bearing oncogenic RAS [406] , able to bind to VDAC2 but not to N-terminal truncated hVDAC2 [407] . Oblimersen (G3139), an anti-sense oligonucleotide being studied as a possible treatment for several types of cancer, including CLL [408] , B-cell lymphoma [409] , breast cancer [410] and melanoma [250] , directly interacts with VDAC to reduce its channel activity [250, 411] . Avicins, a family of triterpenoid saponins shown to selectively inhibit the growth of various tumor cells [412, 413] , target and close VDAC, thus leading to an overall lowering of cell energy metabolism, subsequently pushing these cells towards the apoptotic pathway by permeabilization of the OMM and release of Cyto c [414, 415] . Cisplatin is an anti-cancer drug shown to bind preferentially to mitochondrial membrane proteins, and of these, preferentially to VDAC [416] to modulate its activity [245] . Endostatin is a broad spectrum angiogenesis inhibitor demonstrated to promote PTP opening via VDAC1 [188] . Methyl jasmonate (MJ) is a natural cyclopentanone lipid belonging to the jasmonate (JA) family of plant oxylipin stress hormones (oxygenated fatty acids) [417] . MJ directly interacts with VDAC1 reconstituted into a planar lipid bilayer, reducing channel conductance [291] . One of the major findings concerning MJ was its ability to detach HK from VDAC1 in a time-and dose-dependent fashion. Dissociation of HK from VDAC1 leads to a dissociating of glycolytic and mitochondrial metabolic functions accompanied by cytochrome c release, inhibition of ATP synthesis, and blockage of oxidative phosphorylation, causing a drastic reduction of intracellular ATP levels and overall irreversible bioenergetics damage leading to cell death [291, 418] . Thus, abrogation of the anti-apoptotic activity of the VDAC1-HK complex is an attractive approach to uncouple glycolytic and mitochondrial metabolic functions. It should be noted, however, that MJ can affect multiple targets, causing cell death in varied manners in different cancer cell types and even within the same cancer cell population [419] .
All these drugs were non-systematically identified as acting via VDAC. A more specific approach involving screening for VDACinteracting compounds affecting the pro-apoptotic activity of the protein is needed to identify novel compounds with selectivity for VDAC1.
VDAC1-based cancer therapeutic strategies
A second class of drugs is based on VDAC1-based therapeutic strategies. VDAC1 is over-expressed in highly demanding cancer cells. Being deeply involved in cellular energy and metabolism by serving as Fig. 9 . VDAC1-based anti-cancer therapy approaches. In exploring the function of VDAC1 oligomerization in apoptosis and showing that VDAC1 serves as a target of anti-apoptotic proteins, several VDAC1-based strategies for cancer therapies were developed (see Section 10).
a key regulator of these processes, VDAC offers a unique target for anti-cancer therapies that aim for cancer's trademark cell metabolic and energy reprogramming and unique death evasion strategies. Cancer therapy strategies aimed at thes aspects of VDAC function include siRNA altering the normal functioning of cancer cells and leading to growth arrest, and VDAC1-based peptides that impair energy homeostasis and minimize the self-defense mechanisms of cancer cells. These can, moreover, be used to overcome protective and pro-survival actions taken by cancer cells (Fig. 9 ).
VDAC1-depletion using RNAi
Considering cancer's trademark of cell metabolic and energy reprogramming, processes essential for tumor progression, and the role of VDAC1 as a key regulator of these processes [2, 3, 5, 6, 12, 55] , disrupting cancer energy and metabolism homeostasis via targeting VDAC1 offers an attractive anti-cancer therapy. Indeed, the importance of VDAC1 for cancer cells is further reflected in the finding that silencing VDAC1 expression reduced cellular ATP levels and cell growth [60] . Furthermore, when HeLa cervical cancer cells stably expressing shRNA directed against hVDAC1 were injected into nude mice, the development of a solid tumor was inhibited [420] . It has also been shown that VDAC1 silencing potentiated H 2 O 2 -induced apoptosis and impaired mitochondrial Ca 2+ loading, while silencing VDAC2 had the opposite effects [261] . Furthermore, a single siRNA specific to the human VDAC1 sequence (hVDAC1-siRNA) was shown to silence VDAC1 expression by over 90% at low nanomolar concentrations and inhibit the growth of various cancer cell types, both in vitro and in vivo [421] . In a xenograft lung cancer mouse model, chemically modified VDAC1-siRNA not only inhibited tumor growth but also resulted in tumor regression [421] . As cell treatment with VDAC1-siRNA resulted in a decrease in cell energy production, with tight correlation between cell growth and cellular ATP levels being seen [60] , the dramatic inhibition of cancer cell growth and tumor development seen was due to a disabling of the abnormal metabolic behavior of cancer cells. Thus, considering the high expression level of VDAC1 in tumors (see Section 10.1) and the specificity of VDAC1-siRNA for the inhibition of cancer cell and tumor growth, silencing VDAC1 expression can be considered as a novel strategic therapeutic approach to treat cancer, potentially paving the way for a more effective pipeline of anti-cancer drugs.
VDAC1-based peptides as potential anti-cancer therapy
Defects in the regulation of apoptosis are often associated with disease and drug resistance [422] , with evading apoptosis being a hallmark of cancer [2, 3, 5, 6, 270] . Cancer cells utilize a variety of strategies to limit or circumvent apoptosis, including quenching of the mitochondrial apoptotic pathway by over-expression of anti-apoptotic proteins, such as the Bcl-2 family of proteins and HK, thus preventing the release of Cyto c from mitochondria (see Section 8) [2, 6, 174, 276] . The antiapoptotic activities of HK, Bcl-2, and Bcl-xL involve their interaction with VDAC1 [62, 121, 184, 196, 197, 290] . Thus, targeting unique cancer cell death evasion strategies by activating death pathways and minimizing self-defense mechanisms of the cancer cells are appropriate anti-cancer strategies. One such approach is based on engineered VDAC1-based peptides that interfere with the activity of the prosurvival proteins, Bcl-2, Bcl-Xl and HK [62, 121, 184, 196, 197, 290] .
Via point mutations, VDAC1 domains and amino acids residues important for interaction with HK, Bcl-2 and Bcl-xL were identified and VDAC1-based peptides targeting these interactions were designed [62, 121, 184, 196, 197, 290] . The VDAC1-based cell penetrating peptides Antp-LP4 and N-Terminal-Antp were constructed to contain the cellpenetrating Antp (Penetrating) sequence, a 16 residue-long sequence from the Drosophila antennapedia-homeodomain, fused to a VDAC1derived sequence [290, 423] . These VDAC1-based peptides effectively induced cancer cell death in a panel of genetically characterized cancer cell lines, regardless of cancer type or mutation status with perceived specificity toward cancerous cells [290, 423] . These peptides were found to induce cell death with features characteristic of apoptosis, such as release of Cyto c and morphological changes, including cell shrinkage, membrane blebbing, phosphatidylserine surface exposure, nuclear condensation and fragmentation [290, 423] . The peptides also induced detachment of mitochondria-bound HK, thereby disrupting the overall cellular bioenergetics balance of high energy-demanding cancer cells [290] . The reported results suggest that the peptides possess a triple mode of action, namely energy and metabolism impairment, interference with the action of anti-apoptotic proteins, and triggering cell death, thus allowing multiple steps to be activated, leading to impairment of cell energy and metabolism homeostasis and to apoptosis induction. VDAC1-based peptides thus provide the opportunity for the development of new anti-cancer therapies, allowing for an overcoming of the chemo-resistance of cancer cells.
Perspectives
Delineating the molecular mechanisms underlying the reprogrammed metabolism in human cancers and their cell survival strategies, together with increased understanding of the difficulty in targeting signal transduction of tumors without significant side-effects, are redirecting cancer research efforts to the development of effective new cancer therapies. Thus, the emergence of targeted therapies specifically targeting critical molecules important for cancer cell survival may provide promising means of selectively killing these malignant cells. VDAC1 is one such a target.
The recent studies reviewed here have demonstrated the pivotal roles of mitochondria and VDAC1 in cancer, encouraging prospects for the development of effective therapies. Research accumulated over recent years points to VDAC1 as being much more than simple channels that passively allow the exchange of ions, metabolites and nucleotides to and from mitochondria. Intensive studies have placed VDAC1 at the crossroads between mitochondrial metabolite transport and apoptosis and as an emerging cancer drug target. VDAC1 mediates metabolite cross-talk between mitochondria and the rest of the cell, and as such is integral to mitochondrial ATP production. VDAC1 provides the docking site for mitochondrial-bound HK, a protein that is highly expressed in cancers, with VDAC1-bound HK facilitating and contributing to the metabolic phenotype of cancer cells. In this respect, the up-regulation of HK expression in tumor cells and its binding to VDAC1 provide both a metabolic benefit and apoptosis-suppressive capacity that offers the cell a growth advantage and increases its resistance to chemotherapy. VDAC1 is associated with the mitochondrial pathway of apoptosis, interacting with over-expressed anti-apoptotic proteins present in cancer and mediating the actions of some anti-cancer drugs. In addition, VDAC1 mediates cholesterol transport and distribution in the mitochondrial membrane, with cancer cells exhibiting several fold higher cholesterol levels than do healthy cells. VDAC1 also functions in ROS production and transport to the cytosol, with elevated ROS generation being seen in cancer cells. VDAC1 also functions in mitochondria-ER Ca 2+ signaling during the apoptosis process. These functions, together with VDAC1 being over-expressed in some cancer cells, point to VDAC1 as being a rational target for the development of a new generation of therapeutics. Likewise, a large body of data suggests that cancer cells express high levels of the anti-apoptotic Bcl-2 family of proteins, as well as over-express VDAC1, the binding site of both HK and Bcl-2. As such, the interaction of VDAC with these antiapoptotic proteins also presents a target for anti-cancer drugs.
As a channel, VDAC1 regulates metabolism by mediating metabolite, ion and water movement through the OMM under physiological conditions but is also an apoptotic checkpoint in stress and pathological conditions. This dual function of VDAC1 in both cell metabolism and apoptosis, as mediated by the protein alone and regulated by associated polypeptides, points to VDAC1 as being a rational target for the development of a new generation of therapeutics. Such strategies include interference RNA to down-regulate VDAC1 expression levels [420] , VDAC1-based peptides [155, 197, 288, 290] and small molecules, such as methyl jesmonate [291] . Altogether, VDAC1-based strategies as anti-cancer therapies are expected to be highly effective, even in drug-resistance tumors, and will enhance the sensitivity of cancer cells toward chemotherapies, thereby reducing their side effects.
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